Novel Transporter Protein in Mammal and Utilization of the Same

ABSTRACT

The present invention provides a lipid membrane that contains a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22. Use of the present invention enables screening for a chemical which regulates excretion of a chemical and/or a waste. Furthermore, use of the present invention enables an arbitrary chemical to be tested for nephrotoxicity and/or hepatotoxicity.

TECHNICAL FIELD

The present invention relates to a novel transporter protein in a mammaland utilization of the same. More specifically, the present inventionrelates to a novel organic cation transporter protein responsible forthe final stage of excretion of a chemical and/or a waste andutilization of the same.

BACKGROUND ART

Organisms must process toxic substances in the environment and/orexcretory metabolites. In particular, humans must process drugs and thelike of a very wide variety of structures. In mammals, organic compoundshaving such toxicity are excreted primarily via the kidneys and/or theliver. Excretion in the kidneys occurs through filtration in theglomerulus and secretion in the renal tubules. Organic compounds havingtoxicity are taken up from membrane of the renal tubules cells on thevascular side and excreted from the brush border membrane side of therenal tubules cells (refer to Non-patent Documents 1 to 7). Hepatocytesalso absorb organic compounds having toxicity from the sinusoidalcapillary and excrete them into the capillary bile duct (refer toNon-patent Documents 1 to 7).

To date, many biochemical or biological studies have revealed that aspecific transporter is responsible for the final stage of organiccation (OC) excretion and suggested the existence of an OC transporterwhich mediates exchange transport of electroneutral protons and OCs(refer to Non-patent Documents 5 to 7). This putative transporter isconsidered to be a multidrug recognizing excretion transporter since itrecognizes a wide variety of OCs, several types of vitamins, orendogenous compounds (for example, choline and dopamine) includingcationic chemicals.

The entity of transporters remains unknown so far, and homologues ofknown kidney transporters have been searched to identify its molecularentity. However, no molecule (protein) showing the intended function hasbeen identified. That is, specifically what molecules exist astransporter proteins responsible for the final stage of organic cations(OC) excretion remains unknown, and identification of specific moleculeshas been awaited.

The inventors of the present invention considered that a family ofproteins having the intended function may be conserved in bacteria tomammals and assumed that an orthologue of a protein which functions as amultidrug efflux pump in bacteria exists in mammals, and this orthologueis responsible for OC excretion in mammals.

Multidrug efflux pumps of bacteria are classified into several groups(for example, major facilitator superfamily [MSF], small multidrugresistance [SMR] family, resistance modulation cell division [RND]family, ATP binding cassette [ABC] family, and multidrug and toxinextrusion [MATE] family) (refer to Non-patent Documents 8 to 10).

The inventors of the present invention searched databases from theirunique viewpoints, and, as a result, found out that genes encodingproteins which are likely to be classified into the MATE family proteinsexist in mammals (refer to Non-patent Document 11).

[Non-patent Document 1] Pritchard, J. B. and Miller, D. S. (1993)Physiol. Rev.: 73, 765-96[Non-patent Document 2] Ullrich, K. J. (1994) Biochim. Biophys. Acta:1197, 45-62[Non-patent Document 3] Oude Elferink, R. P., et al. (1995) Biochim.Biophys. Acta: 1241, 215-68[Non-patent Document 4] Koepsell, H. (1998) Annu. Rev. Physiol.: 60,243-66

[Non-patent Document 5] Inui, K. I. Et al., (2000) Kidney Int.: 58,944-58

[Non-patent Document 6] Wright, S. H. and Dantzler, W. H. (2004)Physiol. Rev.: 84, 987-1049[Non-patent Document 7] Koepsell, H. (2004) Trends Pharmacol. Sci.: 25,375-81[Non-patent Document 8] Brown, M. H. et al. (1999) Mol. Microbiol.: 31,394-5[Non-patent Document 9] Putman, M. et al. (2000) Microbiol. Mol. Biol.Rev.: 64, 672-93[Non-patent Document 10] Hvorup, R. N. et al. (2003) Eur. J. Biochem.:270, 799-813[Non-patent Document 11] Genbank accession number AK001709

[Non-patent Document 12] Ito, W. et al. (1991) Gene: 1002, 67-70[Non-patent Document 13] Morimoto, R. et al. (2003) J. Neurochem. 84:382-91 [Non-patent Document 14] Tamai, I. Et al. (1997) FEBS Lett.: 419,107-11

[Non-patent Document 15] Morita, Y. et al. (1998) Antimicrob. AgentsChemother.: 42, 1778-82[Non-patent Document 16] Smith, A. C. et al. (1986) Am. J. Med. Genet.:24, 393-414

[Non-patent Document 17] Bi, W. et al. (2002) Genome Res.: 12, 713-28

The putative amino acid sequence encoded by the gene described inNon-patent Document 11 has a very low sequence homology with theNa⁺-dependent multidrug efflux transporter NorM of Vibrio bacteria, aprototype of the MATE family, and it is hard to presume that thisprotein is classified as a MATE family protein.

Furthermore, the MATE family is a group of recently classified-proteinsrequired for acquisition of multidrug resistance, and only some of themare known to excrete H⁺ or Na⁺-dependent cationic chemicals in bacteria.That is, not only characteristics of the whole MATE family have not beenelucidated yet, but there has been no assay system for identifying atarget protein as a MATE family protein in mammals.

DISCLOSURE OF THE INVENTION

The present invention was accomplished in consideration of theabove-mentioned problems. Objectives of the present invention are toestablish an assay system for identifying MATE family proteins to findMATE family proteins in mammals and to provide a technique utilizingfunctions thereof.

The lipid membrane of the present invention is characterized bycontaining the following polypeptide: a polypeptide consisting of theamino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22; or a polypeptideconsisting of an amino acid sequence wherein one or more amino acids aredeleted, substituted, or added in the amino acid sequence of SEQ ID NO:2, 4, 6, 8, or 22, and having a transporter activity in a cell membrane.

A lipid membrane of the present invention may be a naturally occurringlipid membrane or an artificial lipid membrane. A naturally occurringlipid membrane is preferably a plasma membrane (cell membrane) or amembrane vesicle, and an artificial lipid membrane is preferably aplanar lipid membrane or a liposome.

The transformant of the present invention is characterized in that apolynucleotide encoding a polypeptide consisting of the amino acidsequence of SEQ ID NO: 2, 4, 6, 8, or 22; or a polypeptide consisting ofan amino acid sequence wherein one or more amino acids are deleted,substituted, or added in the amino acid sequence of SEQ ID NO: 2, 4, 6,8, or 22 and having a transporter activity, is introduced thereinto.

In the transformant of the present invention, the above-mentionedpolypeptide may be a polypeptide encoded by a polynucleotide consistingof the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, or 21; or apolypeptide which is encoded by a polynucleotide consisting of anucleotide sequence wherein one or more nucleotides are deleted,substituted, or added in the nucleotide sequence of SEQ ID NO: 1, 3, 5,7, or 21 and has a transporter activity in a plasma membrane.

In the transformant of the present invention, the above-mentionedpolypeptide may also be a polypeptide encoded by a polynucleotideconsisting of the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, or 21;or a polypeptide which is encoded by a polynucleotide hybridizable witha polynucleotide consisting of a nucleotide sequence of SEQ ID NO: 1, 3,5, 7, or 21 under a stringent condition and has a transporter activityin a plasma membrane.

In the transformant of the present invention, the above-mentionedpolypeptide may also be a polypeptide encoded by a polynucleotideconsisting of the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, or 21;or a polypeptide which is encoded by a polynucleotide having a homologyof 80% or more with a polynucleotide consisting of the nucleotidesequence of SEQ ID NO: 1, 3, 5, 7, or 21 and has a transporter activityin a plasma membrane.

The liposome composition of the present invention is characterized bycontaining a polypeptide consisting of the amino acid sequence of SEQ IDNO: 2, 4, 6, 8, or 22; or a polypeptide consisting of an amino acidsequence wherein one or more amino acids are deleted, substituted, oradded in the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22 andhaving a transporter activity in a plasma membrane.

In the liposome composition of the present invention, theabove-mentioned polypeptide may be a polypeptide encoded by apolynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1, 3,5, 7, or 21; or a polypeptide which is encoded by a polynucleotideconsisting of a nucleotide sequence wherein one or more nucleotides aredeleted, substituted, or added in the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, or 21 and having a transporter activity in a plasmamembrane.

In the liposome composition of the present invention, theabove-mentioned polypeptide may also be a polypeptide encoded by apolynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1, 3,5, 7, or 21; or a polypeptide which is encoded by a polynucleotidehybridizable with a polynucleotide consisting of the nucleotide sequenceof SEQ ID NO: 1, 3, 5, 7, or 21 under a stringent condition and has atransporter activity in a plasma membrane.

In the liposome composition of the present invention, theabove-mentioned polypeptide may also be a polypeptide encoded by apolynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1, 3,5, 7, or 21; or a polypeptide which is encoded by a polynucleotidehaving a homology of 80% or more with a polynucleotide consisting of thenucleotide sequence of SEQ ID NO: 1, 3, 5, 7, or 21 and has atransporter activity in a plasma membrane.

The liposome composition of the present invention may further containthe H⁺-ATPase protein. The H⁺-ATPase protein is a protein which activelytransports intracellular protons out of the cell and is also referred toas a proton pump.

The lipid membrane preparation method of the present invention ischaracterized by comprising the step of using a vector containing apolynucleotide coding for the following polypeptide to prepare theabove-mentioned lipid membrane: a polypeptide consisting of the aminoacid sequence of SEQ ID NO: 2, 4, 6, 8, or 22; or a polypeptide whichconsists of an amino acid sequence wherein one or more amino acids aredeleted, substituted or added in an amino acid sequence of SEQ ID NO: 2,4, 6, 8, or 22 and has a transporter activity in a cell membrane.

The lipid membrane preparation kit of the present invention ischaracterized by being provided with a vector containing apolynucleotide coding for the following polypeptide to prepare theabove-mentioned lipid membrane: a polypeptide consisting of the aminoacid sequence of SEQ ID NO: 2, 4, 6, 8, or 22; or a polypeptide whichconsists of an amino acid sequence wherein one or more amino acids aredeleted, substituted, or added in the amino acid sequence of SEQ ID NO:2, 4, 6, 8, or 22 and has a transporter activity in a cell membrane.

The test method of the present invention is characterized by comprisingthe step of incubating the above-mentioned lipid membrane together witha chemical to be evaluated in order to test a chemical fornephrotoxicity and/or hepatotoxicity.

In the above-mentioned incubation step of the test method of the presentinvention, it is preferable to allow tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, or thiamin to coexist.

The test method of the present invention is characterized by comprisingthe step of incubating the above-mentioned transformant together with asubstrate of a polypeptide having a transporter activity in a cellmembrane, in order to test a chemical for nephrotoxicity and/orhepatotoxicity.

In the test method of the present invention, the above-mentionedsubstrate is preferably tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, or thiamin.

The test method of the present invention is characterized by comprisingthe step of incubating the above-mentioned liposome composition togetherwith a substrate of a polypeptide having a transporter activity in acell membrane, in order to test a chemical for nephrotoxicity and/orhepatotoxicity.

In the test method of the present invention, the above-mentionedsubstrate is preferably tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, or thiamin.

The test kit of the present invention is characterized by being providedwith the above-mentioned lipid membrane, in order to test a chemical fornephrotoxicity and/or hepatotoxicity.

The test kit of the present invention may be further provided with atleast one of tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium(MPP), cimetidine, quinidine, verapamil, nicotine, corticosterone,Rhodamine 123, testosterone, melatonin, progesterone, androsterone,quercetin, Rhodamine 6G, chloroquine, quinine, pyrimethamine,chlorpromazine, berberine, cisplatin, propranolol, papaverine, andthiamin.

The test kit of the present invention is characterized by being providedwith the above-mentioned transformant, in order to test a chemical fornephrotoxicity and/or hepatotoxicity.

It is preferable that the test kit of the present invention is furtherprovided with at least one of tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, and thiamin.

The test kit of the present invention is characterized by being providedwith the above-mentioned liposome composition, in order to test achemical for nephrotoxicity and/or hepatotoxicity.

It is preferable that the test kit of the present invention is furtherprovided with at least one of tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, and thiamin.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned lipid membranetogether with a candidate factor, in order to screen for a chemicalwhich regulates substance transport across a plasma membrane.

In the screening method of the present invention, the above-mentionedsubstance transport is preferably transport of nicotine, melatonin, orsteroid hormones or excretion of a chemical and/or a waste.

Furthermore, in the above-mentioned incubation step of the screeningmethod of the present invention, it is preferable to allowtetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine,quinidine, verapamil, nicotine, corticosterone, Rhodamine 123,testosterone, melatonin, progesterone, androsterone, quercetin,Rhodamine 6G, chloroquine, quinine, pyrimethamine, chlorpromazine,berberine, cisplatin, propranolol, papaverine, or thiamin to coexist.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned transformanttogether with a substrate of a polypeptide having a transporter activityin a cell membrane, in order to screen for a chemical which regulatesexcretion of a chemical and/or a waste.

In the screening method of the present invention, the above-mentionedsubstrate is preferably tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, or thiamin.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned liposomecomposition together with a substrate of a polypeptide which has atransporter activity in a cell membrane, in order to screen for achemical which regulates excretion of a chemical and/or a waste.

In the screening method of the present invention, the above-mentionedsubstrate is preferably tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, or thiamin.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned transformanttogether with a substrate of a polypeptide which has a transporteractivity in a cell membrane, in order to screen for a chemical whichregulates nicotine transport.

In the screening method of the present invention, the above-mentionedsubstrate is preferably tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, or thiamin.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned liposomecomposition together with a substrate of a polypeptide which has atransporter activity in a cell membrane, in order to screen for achemical which regulates nicotine transport.

In the screening method of the present invention, the above-mentionedsubstrate is preferably tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, or thiamin.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned transformanttogether with a substrate of a polypeptide which has a transporteractivity in a cell membrane, in order to screen for a chemical whichregulates melatonin transport.

In the screening method of the present invention, the above-mentionedsubstrate is preferably tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, or thiamin.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned liposomecomposition together with a substrate of a polypeptide which has atransporter activity in a cell membrane, in order to screen for achemical which regulates melatonin transport.

In the screening method of the present invention, the above-mentionedsubstrate is preferably tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, or thiamin.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned transformanttogether with a substrate of a polypeptide which has a transporteractivity in a cell membrane, in order to screen for a chemical whichregulates steroid hormone transport.

In the screening method of the present invention, the above-mentionedsubstrate is preferably tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, or thiamin.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned liposomecomposition together with a substrate of a polypeptide which has atransporter activity in a cell membrane to screen for a chemical whichregulates steroid hormone transport.

In the screening method of the present invention, the above-mentionedsubstrate is preferably tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, or thiamin.

The screening kit of the present invention is characterized by beingprovided with the above-mentioned lipid membrane in order to screen fora chemical which regulates substance transport across a cell membrane.

In the screening kit of the present invention, the above-mentionedsubstance transport is preferably transport of nicotine, melatonin, orsteroid hormones or excretion of a chemical and/or a waste.

Furthermore, the screening kit of the present invention may be furtherprovided with tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium(MPP), cimetidine, quinidine, verapamil, nicotine, corticosterone,Rhodamine 123, testosterone, melatonin, progesterone, androsterone,quercetin, Rhodamine 6G, chloroquine, quinine, pyrimethamine,chlorpromazine, berberine, cisplatin, propranolol, papaverine, orthiamin.

The screening kit of the present invention is characterized by beingprovided with the above-mentioned transformant in order to screen for achemical which regulates excretion of a chemical and/or a waste.

It is preferable that the screening kit of the present invention isfurther provided with at least one of tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, and thiamin.

The screening kit of the present invention is characterized by beingprovided with the above-mentioned liposome composition in order toscreen for a chemical which regulates excretion of a chemical and/or awaste.

It is preferable that the screening kit of the present invention isfurther provided with at least one of tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, and thiamin.

The screening kit of the present invention is characterized by beingprovided with the above-mentioned transformant in order to screen for achemical which regulates transport of nicotine.

It is preferable that the screening kit of the present invention isfurther provided with at least one of tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, and thiamin.

The screening kit of the present invention is characterized by beingprovided with the above-mentioned liposome composition in order toscreen for a chemical which regulates nicotine transport.

It is preferable that the screening kit of the present invention isfurther provided with at least one of tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, and thiamin.

The screening kit of the present invention is characterized by beingprovided with the above-mentioned transformant in order to screen for achemical which regulates melatonin transport.

It is preferable that the screening kit of the present invention isfurther provided with at least one of tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, and thiamin.

The screening kit of the present invention is characterized by beingprovided with the above-mentioned liposome composition in order toscreen for a chemical which regulates melatonin transport.

It is preferable that the screening kit of the present invention isfurther provided with at least one of tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, and thiamin.

The screening kit of the present invention is characterized by beingprovided with the above-mentioned transformant in order to screen for achemical which regulates steroid hormone transport.

It is preferable that the screening kit of the present invention isfurther provided with at least one of tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, and thiamin.

The screening kit of the present invention is characterized by beingprovided with the above-mentioned liposome composition in order toscreen for a chemical which regulates steroid hormone transport.

It is preferable that the screening kit of the present invention isfurther provided with at least one of tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, and thiamin.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned lipid membranetogether with a candidate factor in order to screen for a substrate of apolypeptide which has a transporter activity in a cell membrane.

Furthermore, in the above-mentioned incubation step of the screeningmethod of the present invention, it is preferable to allowtetraethylammonium (TEA) or 1-methyl-4-phenylpyridinium (MPP) tocoexist.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned transformanttogether with tetraethylammonium (TEA) or 1-methyl-4-phenylpyridinium(MPP) in order to screen for a substrate of a polypeptide which has atransporter activity in a cell membrane.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned liposomecomposition together with tetraethylammonium (TEA) or1-methyl-4-phenylpyridinium (MPP) in order to screen for a substrate ofa polypeptide which has a transporter activity in a cell membrane.

The screening kit of the present invention is characterized by beingprovided with the above-mentioned lipid membrane in order to screen fora substrate of a polypeptide which has a transporter activity in a cellmembrane.

Furthermore, the screening kit of the present invention may be furtherprovided with tetraethylammonium (TEA) or 1-methyl-4-phenylpyridinium(MPP).

The screening kit of the present invention is characterized by beingprovided with the above-mentioned transformant in order to screen for asubstrate of a polypeptide which has a transporter activity in a cellmembrane.

It is preferable that the screening kit of the present invention isfurther provided with tetraethylammonium (TEA) or1-methyl-4-phenylpyridinium (MPP).

The screening kit of the present invention is characterized by beingprovided with the above-mentioned liposome composition in order toscreen for a substrate of a polypeptide which has a transporter activityin a cell membrane.

It is preferable that the screening kit of the present invention isfurther provided with tetraethylammonium (TEA) or1-methyl-4-phenylpyridinium (MPP).

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned transformanttogether with a candidate compound in order to screen for an inhibitoror an activity enhancer of a polypeptide having a transporter activityin a cell membrane.

The screening kit of the present invention is characterized by beingprovided with the above-mentioned transformant in order to screen for aninhibitor or an activity enhancer of a polypeptide having a transporteractivity in a cell membrane.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned liposomecomposition together with a candidate compound in order to screen for aninhibitor or an activity enhancer of a polypeptide having a transporteractivity in a cell membrane.

The screening kit of the present invention is characterized by beingprovided with the above-mentioned liposome composition in order toscreen for an inhibitor or an activity enhancer of a polypeptide havinga transporter activity in a cell membrane.

The diagnosis method of the present invention is characterized bycomprising the step of hybridizing a fragment of any of the followingpolynucleotides or an oligonucleotide which consists of at least 12continuous nucleotides complementary thereto with mRNA prepared from abiological sample in order to diagnose a disease caused by abnormalsubstance transport across a cell membrane:

a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1,3, 5, 7, or 21;

a polynucleotide consisting of a nucleotide sequence wherein one or morenucleotides are deleted, substituted, or added in the nucleotidesequence of SEQ ID NO: 1, 3, 5, 7, or 21;

a polynucleotide which hybridizes with a polynucleotide consisting of anucleotide sequence complementary to the nucleotide sequence of SEQ IDNO: 1, 3, 5, 7, or 21 under a stringent condition; or

a polynucleotide consisting of a nucleotide sequence at least 80%identical to the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, or 21.

In the diagnosis method of the present invention, the above-mentionedoligonucleotide preferably consists of any one of the nucleotidesequences of SEQ ID NOS: 11 to 18.

The diagnosis kit of the present invention is characterized by beingprovided with an oligonucleotide which is a fragment of any of thefollowing polynucleotides or an oligonucleotide which consists of atleast 12 continuous nucleotides complementary thereto in order todiagnose a disease caused by abnormal substance transport across a cellmembrane:

a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1,3, 5, 7, or 21;

a polynucleotide consisting of a nucleotide sequence wherein one or morenucleotides are deleted, substituted, or added in the nucleotidesequence of SEQ ID NO: 1, 3, 5, 7, or 21;

a polynucleotide which hybridizes with a polynucleotide consisting of anucleotide sequence complementary to the nucleotide sequence of SEQ IDNO: 1, 3, 5, 7, or 21 under a stringent condition; or

a polynucleotide consisting of a nucleotide sequence at least 80%identical to the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, or 21.

In the diagnosis kit of the present invention, the above-mentionedoligonucleotide preferably consists of any one of nucleotide sequencesof SEQ ID NOS: 11 to 18.

The diagnosis method of the present invention is characterized bycomprising the step of incubating an antibody specifically binding toany of the following polypeptides together with a biological sample inorder to diagnose a disease caused by abnormal substance transportacross a cell membrane:

a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4,6, 8, or 22; or

a polypeptide which consists of an amino acid sequence wherein one ormore amino acids are deleted, substituted, or added in the amino acidsequence of SEQ ID NO: 2, 4, 6, 8, or 22 and has a transporter activityin a cell membrane.

In the diagnosis method of the present invention, the above-mentionedantibody is preferably elicited by a peptide consisting of the aminoacid sequence of SEQ ID NO: 19 or 20.

The diagnosis method of the present invention is characterized bycomprising the step of using an antibody specifically binding to apolypeptide having a transporter activity in a cell membrane in order todiagnose a disease caused by abnormal substance transport involving apolypeptide having a transporter activity in a cell membrane, whereinthe polypeptide is a polypeptide consisting of the amino acid sequenceof SEQ ID NO: 2, 4, 6, 8, or 22 or a polypeptide which consists of anamino acid sequence wherein one or more amino acids are deleted,substituted or added in the amino acid sequence of SEQ ID NO: 2, 4, 6,8, or 22 and has a transporter activity in a cell membrane.

The diagnosis kit of the present invention is characterized by beingprovided with an antibody specifically binding to any of the followingpolypeptides in order to diagnose a disease caused by abnormal substancetransport across a cell membrane:

a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4,6, 8, or 22; or

a polypeptide which consists of an amino acid sequence wherein one ormore amino acids are deleted, substituted, or added in the amino acidsequence of SEQ ID NO: 2, 4, 6, 8, or 22 and has a transporter activityin a cell membrane.

In the diagnosis kit of the present invention, the above-mentionedantibody is preferably elicited by a peptide consisting of the aminoacid sequence of SEQ ID NO: 19 or 20.

The diagnostic kit of the present invention is characterized by beingprovided with an antibody specifically binding to a polypeptide having atransporter activity in a cell membrane in order to diagnose a diseasecaused by abnormal substance transport involving a polypeptide having atransporter activity in a cell membrane, wherein the polypeptide is apolypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4, 6,8, or 22, or a polypeptide which consists of an amino acid sequencewherein one or more amino acids are deleted, substituted or added in theamino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22 and has atransporter activity in a cell membrane.

The polypeptide of the present invention is characterized by being apolypeptide consisting of the amino acid sequence of SEQ ID NO: 22, or apolypeptide which consists of an amino acid sequence wherein one or moreamino acids are deleted, substituted, or added in the amino acidsequence of SEQ ID NO: 22 and has a transporter activity in a cellmembrane.

The polynucleotide of the present invention is characterized by encodingthe above-mentioned polypeptide.

Furthermore, the polynucleotide of the present invention can be apolynucleotide consisting of the nucleotide sequence of SEQ ID NO: 21; apolynucleotide consisting of a nucleotide sequence wherein one or morenucleotides are deleted, substituted, or added in the nucleotidesequence of SEQ ID NO: 21; a polynucleotide hybridizable with apolynucleotide consisting of a nucleotide sequence complementary to thenucleotide sequence of SEQ ID NO: 21 under a stringent condition; or apolynucleotide consisting of a nucleotide sequence being at least 80%identical to the nucleotide sequence of SEQ ID NO: 21.

The vector of the present invention is characterized by comprising theabove-mentioned polynucleotide.

The transformant of the present invention is characterized by comprisingthe above-mentioned polynucleotide.

The antibody of the present invention is characterized by specificallybinding to the above-mentioned polypeptide.

The knockout animal of the present invention is characterized in thatthe expression of a polypeptide consisting of the amino acid sequence ofSEQ ID NO: 2, 4, 6, 8, or 22 is inhibited, and it is preferably a mouse.

Other objectives, features, and advantages of the present invention willbe fully understood from the following descriptions. Furthermore,benefits of the present invention will be apparent from the followingdescription with reference to the accompanying drawings.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows positions and constitutions of the hMATE1 gene, the hMATE2gene, and the hMATE3 gene on the chromosome.

FIG. 2 shows alignments of the amino acid sequences of hMATE1, hMATE2,and hMATE3 and the amino acid sequence of the bacterium-derived NorM. Itis shown that the E273 residue, which is important for a transportactivity, is conserved in all the sequences.

FIG. 3 is a scheme showing a putative secondary structure of hMATE1. Inthe figure, the glutamic acid residue (E273), which is important for atransport activity, is encircled.

FIG. 4( a) shows the results of the northern blot analysis examining theexpressions of the hMATE1 gene and the hMATE2 gene in humans. It isshown that the hMATE1 gene is expressed primarily in the kidneys, theliver, and the skeletal muscles, while the hMATE2 gene is expressed inthe kidneys.

FIG. 4( b) shows the results of the western blot analysis confirming theexpression of hMATE1 using an anti-hMATE1 antibody. The anti-hMATE1antibody specifically recognizes hMATE1 expressed in the HEK293 cell.Furthermore, a protein having an identical size exists in the kidneys,and detection of this protein by the anti-hMATE1 antibody is absorbed bythe antigen peptide (N461-R546 of hMATE1)

FIG. 4( c) shows the results of the immunohistochemistry of hMATE1 inthe kidneys. A human specimen section was stained by the HRP-DAB method.In the figure, PCT denotes proximal renal tubule, and DCT denotes distalrenal tubule. The bar is 100 μm.

FIG. 4( d) shows the results of the immunohistochemistry of hMATE1 inthe liver. The human sample section was stained by the HRP method. Thebar is 100 μm.

FIG. 5 shows positions and constitutions of the mMATE1 gene and themMATE2 gene on the chromosome.

FIG. 6 shows alignments of the amino acid sequences of mMATE1 and mMATE2and the amino acid sequence of hMATE1. In the figure, an asteriskindicates the identical amino acid. E273 is glutamic acid, an amino acidimportant for a transport activity.

FIG. 7( a) shows the results of the northern blot analysis of theexpressions of the mMATE1 gene and the mMATE2 gene in various organs. Itwas shown that the mMATE1 gene was expressed primarily in the kidneysand liver, and the mMATE2 gene was expressed in the testicle.

FIG. 7( b) shows the results of the western blot analysis using ananti-mMATE1 antibody confirming the expression of mMATE1. Theanti-mMATE1 antibody specifically recognizes mMATE1 expressed in theHEK293 cell. Furthermore, a protein having an identical size exists inthe kidneys and the liver.

FIG. 7( c) shows the results of the immunohistochemistry of mMATE1 inthe kidneys. A mouse specimen section was stained by the HRP-DAB method.mMATE1 is expressed in the renal cortex. In the figure, GL denotesglomerulus, PCT denotes proximal renal tubule, DCT denotes distal renaltubule, and CCD denotes cortical collecting duct. The bar is 100 μm.

FIG. 7( d) shows results of the immunohistochemistry of mMATE1 in thekidneys. A mouse specimen section was stained by the HRP-DAB method.mMATE1 is expressed in the renal medulla.

FIG. 8( a) shows an immunoelectron microscopic image of mMATE1 in thekidneys. mMATE1 exists in the epidermis (membrane portion) of the renaltubules. In the figure, BBM denotes brush border membrane, BM denotesbasement membrane, M denotes mitochondrion, and L denotes lumen. The baris 1 μm.

FIG. 8( b) shows an indirect immunofluorescence microscopic image ofmMATE1 in the liver (capillary bile duct membrane)

FIG. 8( c) shows the indirect immunofluorescence microscopic image ofmMATE1 in the liver (epidermal side of the bile duct membrane). In thefigure, BD denotes interlobular bile duct, and HPV denotes portal vein.The bar is 10 μm.

FIG. 9( a) shows immunofluorescence microscopic images of wild type(Wild) and mutant (E273Q) hMATE1 expressed in the HEK293 cells.

FIG. 9( b) is a graph showing the results of the observation of uptakeof TEA (50 μM) into the cell shown in FIG. 9( a) at pH 8.0 over time.

FIG. 9( c) is a graph showing the results of the observation of TEAtransport at various concentrations. The value in cells transfected withonly a plasmid (Mock) is deducted from the values in cells expressingthe wild type hMATE1.

FIG. 9( d) is a graph showing the results of the observation of TEAtransport at various pH.

FIG. 9( e) is a graph showing effect of Na⁺ on TEA transport.

FIG. 9( f) is a graph showing the results of the observation of effectof pH on TEA excretion.

FIG. 10 is a graph showing that MATE1 functions as a nicotinetransporter.

FIG. 11 shows the results of CBB-stained gel after electrophoresis ofthe sample at each purification step of hMATE1 purified using abaculovirus system.

FIG. 12 shows changes over time in TEA transport determined using aliposome containing a MATE polypeptide.

FIG. 13 is a scheme showing that MATE1 is a multidrug transporting OCtransporter responsible for the final stage of OC excretion. In theliver, hepatocytes take up OCs via OCT1 and OCT2, organic cationtransporters, in the sinusoidal membrane and excrete them in the bilevia MATE1 and MDR1. In the kidneys, OCs are taken up primarily by renaltubule cells via OCT2 and excreted via MATE1, MDR1, and OCTN2.

FIG. 14 shows the result of fluorescence staining of mMATE1 in the mousealveolar epithelial cell.

FIG. 15 shows the result of fluorescence staining of mMATE1 in thecerebral capillary blood vessel. In the figure, the bar is 10 μm.

FIG. 16 shows the results of staining of hMATE1 in human alveolarepithelial cells by the HRP method. In the figure, the bar is 10 μm.

FIG. 17 shows localization of mMATE1 in the skin. It is shown thatmMATE1 exists in the sebaceous gland. In the figure, the bar is 10 μm.

FIG. 18 shows localization of mMATE1 in the pineal body. It is shownthat mMATE1 exists in the pinealocyte. In the figure, the bar is 10 μm.

FIG. 19 shows localization of mMATE2 in the plasma membrane of atesticle Leydig cells. In the figure, the bar is 10 μm.

FIG. 20 shows the results of the examination of expression levels of thehMATE3 gene in the testicle, skeletal muscles, kidneys, and liver byRT-PCR. It is shown that the hMATE3 gene is expressed only in thetesticle as in the case of mMATE2.

BEST MODE OF CARRYING OUT THE INVENTION

To confirm that the protein that is presumed to be encoded by the genesdescribed in Non-patent Document 11 actually exists in mammals, and thatthe proteins are MATE family proteins, the inventors of the presentinvention attempted to obtain the genes from mammals and constructed anassay system necessary for confirming the function as a MATE familyprotein.

Various primers were designed based on the above-mentioned nucleotidesequence information of the genes, and RT-PCR was attempted using mammaltissues. However, since little information about MATE family moleculeshave been obtained, and, in particular, no specific function domainexists in MATE family molecules, there was no guideline for designingpreferable primers.

However, the inventors of the present invention repeated trials anderrors to verify the reliability of their unique focus. As a result,they finally found that target genes can be amplified using specificprimers.

Thus, the inventors of the present invention found that the genesobtained based on their unique focus and trials and errors exist inhumans and mice, and the proteins encoded by these genes exist inlumen-side membranes of the renal tubules in the kidneys and the bileduct and function as novel transporters.

That is, the inventors of the present invention identified mammal MATEpolypeptides, orthologues of the bacteria-derived MATE family in humansand mice, and found that the mammal MATE polypeptides are expressed inthe kidneys and/or liver and are responsible for the final stage ofexcretion of organic cationic compounds by exchange transport withprotons. Thus, the present invention was accomplished.

[1] Mammal MATE Polypeptides and Polynucleotides

The inventors of the present invention found that an orthologue of thetoxic substance excretion transporter found in the bacteria exist inmammals, isolated the cDNA thereof, and analyzed the functions thereof.

The present invention provides mammal MATE polypeptides. The term “MATEpolypeptide” used in the present specification is used interchangeablywith “MATE protein” or “MATE family protein” and means a polypeptidethat has the MATE activity, in other words, a polypeptide having atransporter activity (transport activity) of transporting organiccations (OCs) via a cell membrane. That is, the term “MATE activity”used in the present specification means a transporter activity in a cellmembrane (activity of transporting a substance via cell membrane), morespecifically, a transporter activity (transport activity) oftransporting organic cations (OCs) via a cell membrane.

The term “polypeptide” used in the present specification is usedinterchangeably with “peptide” or “protein.” Furthermore, the “fragment”of a polypeptide means a partial fragment of the polypeptide. Thepolypeptide of the present invention may be chemically synthesized orisolated from a natural supply source.

The term “isolated” polypeptide or protein means a polypeptide or aprotein retrieved from the natural environment. For example, arecombinant polypeptide or protein expressed in the host cell isconsidered to be isolated as in the case of a natural or recombinantpolypeptide or protein substantially purified by an arbitraryappropriate technique.

The polypeptides of the present invention include natural purificationproducts, chemical synthesis products, and products produced byprokaryotic hosts or eukaryotic hosts (including bacteria cells, yeastcells, higher plant cells, insect cells, and mammal cells) usingrecombination techniques.

The polypeptide of the present invention may be obtained by introducingthe polynucleotide of the present invention described later (the geneencoding the polypeptide of the present invention) into a host cell andexpressing the polypeptide in the cell or by isolation from a cell, atissue, or the like and purification.

Furthermore, the polypeptide of the present invention may contain anadditional peptide. Examples of the additional peptide include peptideslabeled with an epitope such as His, Myc, or Flag. In a preferableembodiment, the polypeptide of the present invention can be expressed asa recombinant in a modified form such as a fusion protein. For example,since additional amino acids of the peptide of the present invention, inparticular, a region of charged amino acids can be added to the N or Cterminus of the polypeptide to improve stability and prolonged-action inthe host cell during purification or subsequent procedures and storage.

Preferably, the mammal MATE polypeptide of the present invention can bea polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4,6, 8, or 22 or a mutant thereof. As the above-mentioned mammals, humansor mice are preferred. The term “mutant” used for a polypeptide or aprotein in the present specification means a polypeptide or a proteinhaving the MATE activity. The amino acid sequences of the human MATE1polypeptide (hMATE1), the human MATE2 polypeptide (hMATE2), the mouseMATE1 polypeptide (mMATE1), the mouse MATE2 polypeptide (mMATE2), andthe human MATE3 polypeptide (hMATE3) are shown in SEQ ID NOS: 2, 4, 6,8, and 22, respectively. Furthermore, the hMATE3 polypeptide is a novelpolypeptide that has been unknown.

In one embodiment, the polypeptide of the present invention is a MATEpolypeptide or a mutant thereof. Here, the mutant is preferably apolypeptide having the MATE activity, which consists of an amino acidsequence wherein one or more amino acids are deleted, substituted, oradded in the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22.

Examples of such mutant include mutants having deletion, insertion,inversion, repetition, and type substitution (for example, substitutionof a hydrophilic residue by another residue. Usually, however, a highlyhydrophilic residue is not substituted by a highly hydrophobic residue).In particular, “neutral” amino acid substitution in a polypeptidegenerally has almost no effect on the activity of the polypeptide.

It is known in this field that several amino acids in the amino acidsequence of a polypeptide can be easily modified without significantlyaffecting the structure or the function of this polypeptide.Furthermore, it is also known that there are not only artificiallymodified polypeptides, but also naturally occurring protein mutants inwhich the structure or the function of the protein is not significantlychanged.

Those skilled in the art can easily mutate one or several amino acids inthe amino acid sequence of a polypeptide using a known technique. Forexample, an arbitrary nucleotide in a polynucleotide encoding apolypeptide can be mutated according to a known point mutagenesismethod. Furthermore, a deletion mutant or an addition mutant can beprepared by designing primers corresponding to an arbitrary site in apolynucleotide encoding a polypeptide. Furthermore, using the methodsdescribed in the present specification, it can be easily determinedwhether the prepared mutant has a desired MATE activity.

Preferred mutants have conservative or nonconservative substitution,deletion, or addition of amino acids. Silent substitution, addition, anddeletion are preferred, and conservative substitution is particularlypreferred. These mutations do not change the MATE activity of thepolypeptide of the present invention.

Representative conservative substitutions appear to include substitutionof one amino acid by another amino acid among aliphatic amino acids,Ala, Val, Leu, and Ile, exchange of hydroxyl residues, Ser and Thr,exchange of acidic residues, Asp and Glu, substitution between amideresidues, Asn and Gln, exchange of basic residues, Lys and Arg, andsubstitution between aromatic residues, Phe and Tyr.

In one embodiment, the polypeptide of the present invention is a MATEpolypeptide or a mutant thereof. Here, the mutant is preferably apolypeptide which has the MATE activity and is encoded by apolynucleotide consisting of a nucleotide sequence wherein one or morenucleotides are deleted, substituted, or added in the nucleotidesequence of SEQ ID NO: 1, 3, 5, 7, or 21.

In another embodiment, the polypeptide of the present invention is aMATE polypeptide or a mutant thereof. Here, the mutant is preferably apolypeptide which has the MATE activity and is encoded by apolynucleotide hybridizable with a polynucleotide consisting of anucleotide sequence complementary to the nucleotide sequence of SEQ IDNO: 1, 3, 5, 7, or 21 under a stringent condition.

Hybridization can be performed by known methods such as the methoddescribed in Sambrook et al., Molecular Cloning, A Laboratory Manual, 2dEd., Cold Spring Harbor Laboratory (1989). Usually, stringency increases(becomes hard to hybridize) at a higher temperature or at a lower saltconcentration, resulting in obtaining of a more homologouspolynucleotide. An appropriate hybridization temperature variesdepending on the nucleotide sequence and the length of the nucleotidesequence. For example, when a DNA fragment consisting of 18 nucleotidescoding for six amino acids is used as a probe, temperature is preferably50° C. or below.

The term “stringent (hybridization) condition” used in the presentspecification means that polynucleotides are incubated in ahybridization solution (containing 50% formamide, 5×SSC [150 mM NaCl, 15mM trisodium citrate], 50 mM sodium phosphate [pH 7.6], 5× Denhart'ssolution, 10% dextran sulfate, and 20 μg/ml sheared denatured salmonsperm DNA) overnight at 42° C., and then the filter is washed with0.1×SSC at about 65° C. A polynucleotide hybridizable with “a part” ofthe polynucleotide means a polynucleotide (either DNA or RNA)hybridizable with at least about 15 nucleotides (nt) of the referencepolynucleotide, more preferably at least about 20 nt, yet morepreferably at least about 30 nt, yet more preferably longer than about30 nt. The polynucleotide (oligonucleotide) hybridizable with “a part”of such polynucleotide is also useful as a detection probe discussed indetail in the present specification.

In another embodiment, the polypeptide of the present invention is aMATE polypeptide or a mutant thereof. Here, the mutant is preferably apolypeptide that has the MATE activity and is encoded by apolynucleotide consisting of a nucleotide sequence at least 80%identical, more preferably at least 85%, 90%, 92%, 95%, 96%, 97%, 98%,or 99% identical to the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, or21.

For example, the expression “a polynucleotide consisting of a nucleotidesequence at least 95% identical to the reference (QUERY) nucleotidesequence of a polynucleotide coding for the polypeptide of the presentinvention” means that the target nucleotide sequence is identical to thereference sequence except that it can comprises up to five mismatchesper 100 nucleotides (bases) of the reference nucleotide sequence of thepolynucleotide coding for the polypeptide of the present invention. Inother words, to obtain a polynucleotide consisting of a nucleotidesequence at least 95% identical to the reference nucleotide sequence, upto 5% of nucleotides in the reference sequence can be deleted orsubstituted by another nucleotide, or many nucleotides which account forup to 5% of all nucleotides in the reference sequence can be insertedinto the reference sequence. These mismatches in the reference sequencecan occur anywhere between the two ends, for example, mismatches aredispersed at the 51 or 3′ end position of the reference nucleotidesequence, at individual nucleotides in the reference sequence, or in agroup of one or more adjacent nucleotides in the reference sequence.

The present invention also provides MATE polynucleotides. The term “MATEpolynucleotide” used in the present specification means a polynucleotideconsisting of the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, or 21 ora mutant thereof. The term “mutant” of DNA or polynucleotide used in thepresent specification means a polynucleotide coding for a polypeptidehaving the MATE activity. The nucleotide sequences of human MATE1polynucleotide, the human MATE2 polynucleotide, the mouse MATE1polynucleotide, the mouse MATE2 polynucleotide, and the human MATE3polynucleotide are shown in SEQ ID NOS: 1, 3, 5, 7, and 21,respectively. Furthermore, the hMATE3 polynucleotide is a novelpolynucleotide that has been unknown.

The term “polynucleotide” used in the present specification can be usedinterchangeably with “gene” “nucleic acid” or “nucleic acid molecule”and means a nucleotide polymer. The term “nucleotide sequence” used inthe present specification is used interchangeably with “nucleic acidsequence” or “base sequence”, and represented by a sequence ofdeoxyribonucleotides (abbreviated as A, G, C, and T) or ribonucleotides(C, A, G, and U). Furthermore, the expression “polynucleotide comprisingthe nucleotide sequence of SEQ ID NO: 1 or a fragment thereof” means apolynucleotide comprising a sequence represented by deoxynucleotides A,G, C, and/or T in SEQ ID NO: 1 or a fragment portion thereof.

The polynucleotide of the present invention can exist in the form of RNA(for example, mRNA) or in the form of DNA (for example, cDNA or genomicDNA). DNA can be double-stranded or single-stranded. A single-strandedDNA or RNA can be a coding strand (also known as a sense strand) or anoncoding strand (also known as an antisense strand).

The term “oligonucleotide” used in the present specification meansseveral to several tens of nucleotides which are bound together and isused interchangeably with “polynucleotide”. A short oligonucleotide isreferred to as dinucleotide (dimer) or trinucleotide (trimer), andlonger ones are represented by the number of polymerized nucleotidessuch as 30 mer or 100 mer. An oligonucleotide may be generated as afragment of a longer polynucleotide or chemically synthesized.

The polynucleotide of the present invention can be fused with apolynucleotide coding for the above-mentioned tag label (tag sequence ormarker sequence) at the 5′ or 3′ end side thereof.

In one embodiment, the polynucleotide of the present invention is a MATEpolynucleotide or a mutant thereof. Here, the mutant preferably codesfor a MATE polypeptide and is any of the following polynucleotides:

a polynucleotide consisting of a nucleotide sequence wherein one or morenucleotides are deleted, substituted, or deleted in the nucleotidesequence of SEQ ID NO: 1, 3, 5, 7, or 21;

a polynucleotide hybridizable with a polynucleotide consisting of anucleotide sequence complementary to the nucleotide sequence of SEQ IDNO: 1, 3, 5, 7, or 21 under a stringent condition; and

a polynucleotide consisting of a nucleotide sequence at least 80%identical, more preferably at least 85%, 90%, 92%, 95%, 96%, 97%, 98%,or 99% identical to the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, or21.

In another embodiment, the polynucleotide of the present invention ischaracterized by being amplified from the human cDNA library using aprimer pair of a primer consisting of the nucleotide sequence of SEQ IDNO: 11 and a primer consisting of the nucleotide sequence of SEQ ID NO:12 or a primer pair of a primer consisting of the nucleotide sequence ofSEQ ID NO: 13 and a primer consisting of the nucleotide sequence of SEQID NO: 14, or a polynucleotide amplified from the mouse cDNA libraryusing a primer pair of a primer consisting of the nucleotide sequenceSEQ ID NO: 15 and a primer consisting of the nucleotide sequence of SEQID NO: 16 or a primer pair of a primer consisting of the nucleotidesequence of SEQ ID NO: 17 and a primer consisting of the nucleotidesequence of SEQ ID NO: 18, and coding for a polypeptide having the MATEactivity.

The polynucleotide of the present invention may comprise sequences suchas the sequence of an untranslated region (UTR) or a vector sequence(including the expression vector sequence).

Supply sources to obtain the polynucleotide of the present invention arenot particularly limited, but biological materials (for example, organsof a human or a mouse) are preferred. The term “biological materials”used in the present specification means biological samples (tissue orcell samples obtained from an organism).

As described in the present specification, the polypeptide or thepolynucleotide of the present invention can be used as a tool fordetermining the MATE activity.

That is, an objective of the present invention is to provide MATEpolypeptides and MATE polynucleotides, not the polypeptide preparationmethods, the polynucleotide preparation methods, and the likespecifically described in the present specification. Therefore, itshould be noted that MATE polypeptides and MATE polynucleotides obtainedby methods other than any of the above-mentioned methods are alsoencompassed in the technical scope of the present invention.

[2] Utilization of Polypeptide and Polynucleotide [2-1] Vector

The present invention provides a vector used for generation of a MATEpolypeptide. The vector of the present invention may be a vector usedfor in vitro translation or a vector used for recombinant expression.

The vector of the present invention is not particularly limited so longas it comprises the above-mentioned polynucleotide of the presentinvention. Examples thereof include recombinant expression vectors intowhich cDNA of a polynucleotide coding for a polypeptide having the MATEactivity (MATE polynucleotide) is inserted and so forth. Examples of therecombinant expression vector preparation method include, but are notparticularly limited to, methods using a plasmid, a phage, or a cosmid.

Specific types of the vector are not particularly limited, and vectorsexpressible in a host cell can be suitably selected. Specifically, asuitable promoter sequence is selected depending on the type of the hostcell to reliably express the polynucleotide of the present invention,and a vector obtained by incorporating this sequence and thepolynucleotide of the present invention into various plasmids or thelike can be used as an expression vector. Furthermore, the host can alsobe transformed with an expression vector by conventional methods.

A host transformed with the above-mentioned expression vector can becultured, cultivated or bred, and then a target protein can be recoveredfrom a culture and purified using conventional methods (for example,filtration, centrifugation, cell crush, gel filtration chromatography,ion exchange chromatography, etc.).

The expression vector preferably comprises at least one selectionmarker. Examples of such markers include dihydrofolic acid reductase orneomycin resistance for eukaryotic cell culture, as well as thetetracycline-resistance gene or the ampicillin resistance gene forculture of E. coli and other bacteria.

By using the vector of the present invention, a MATE polypeptide can beexpressed in an organism or a cell by introducing the MATEpolynucleotide into the organism or the cell. Furthermore, a MATEpolypeptide can be synthesized by using the vector of the presentinvention in a cell-free protein synthesis system.

Thus, it is sufficient that the vector of the present inventioncomprises at least a polynucleotide coding for the polypeptide of thepresent invention. That is, it should be noted that vectors other thanexpression vectors are also encompassed in the technical scope of thepresent invention.

[2-2] Lipid Membrane

The present invention provides a lipid membrane containing a MATEpolypeptide. The lipid membrane of the present invention may be anaturally occurring lipid membrane or an artificial lipid membrane. Whenthe lipid membrane of the present invention is naturally occurring, itis sufficient that the membrane is a cell membrane or a membranevesicle. When the lipid membrane of the present invention is artificial,it is sufficient that the membrane is a planar lipid membrane or aliposome (liposome composition).

(a) Transformant

In one embodiment, the lipid membrane of the present invention can be aplasma membrane of a transformant into which a polynucleotide coding fora MATE polypeptide is introduced. The term “transformant” used in thepresent specification means not only a cell, a tissue, or an organ, butincludes an organism.

The transformant of this embodiment is characterized in that a plasmamembrane containing a MATE polypeptide is formed. It is preferable thata MATE polypeptide is stably expressed in the transformant in thepresent embodiment.

In one aspect, the transformant of this embodiment is obtained byintroducing a recombinant vector containing a MATE polynucleotide intoan organism so that the MATE polypeptide can be expressed. Thetransformant in this embodiment may be a prokaryote or a eukaryote.Since the analysis by the inventors of the present invention showed thata MATE polypeptide is a membrane protein, a plasma membrane containing aMATE polypeptide is provided in a transformant in which a MATEpolypeptide is expressed.

The method for introducing the above-mentioned expression vector into ahost, that is, the transformation method is not particularly limited,and conventionally known methods such as electroporation, the calciumphosphate method, the liposome method, and the DEAE dextran method canbe suitably used. Furthermore, for example, to transform an insect cellwith the polypeptide of the present invention, an expression systemusing baculovirus can be used. To transform a plant with the polypeptideof the present invention, a polynucleotide coding for the polypeptide ofthe present invention can be introduced by the Agrobacterium method orthe gene gun method (particle bombardment method).

Thus, it is sufficient that at least a plasma membrane containing thepolypeptide of the present invention is formed in the transformant ofthe present embodiment. That is, it should be noted that transformantsprepared by known methods other than the above-mentioned methods arealso encompassed in the technical scope of the present invention.

(b) Membrane Vesicle

In one embodiment, the lipid membrane of the present invention can be amembrane vesicle obtained from a cell into which a polynucleotide codingfor a MATE polypeptide is introduced. The “membrane vesicle” used in thepresent specification means a smaller vesicle formed by a plasmamembrane of a cell subjected to ultrasonication or the like anddestroyed.

Thus, it is sufficient that the membrane vesicle of the presentembodiment is at least formed by a lipid membrane containing thepolypeptide of the present invention. That is, it should be noted thatmembrane vesicles containing an intracellular organelle that has lostthe function thereof or the like are also encompassed in the technicalscope of the present invention.

(c) Liposome and Liposome Composition

A MATE polypeptide is a transporter that transports various organiccations (OCs). So far, the inventors of the present invention examinedsubstances transported by the MATE polypeptide in a system of the HEK293cell or Africa Xenopus laevis oocyte in which MATE polypeptide wasexpressed using radiolabeled substrates. In such a system usingexpression cells, many cell-derived proteins coexist in addition to theMATE polypeptide, and interference of many coexisting proteins isparticularly problematic when highly hydrophobic transport substratessuch as sex hormones or the like are used. That is, to measure highlyhydrophobic transport substrates with high reliability, it is preferableto use a system in which no protein other than the MATE polypeptideexists.

Furthermore, since labeled substances (specifically, radiolabeledsubstances or fluorescence-labeled substances) are used as transportsubstrates in the above-described experimental system, transport oftransporter proteins which transport chemicals, toxic substances,metabolic biological components, and the like which cannot be labeledcould not be confirmed.

Therefore, the inventors of the present invention prepared almostproteomically uniform MATE polypeptides and a liposome in which they areincorporated (so-called proteoliposome) and completed a MATE polypeptidetransport assay system constituted by a completely defined compositionby subjecting this proteoliposome to a transport experiment. Then, byusing a mass spectroscopy (a mass spectrometer), a fluorescencespectrometer, HPLC, and the like in combination, this transport assaysystem can correctly examine whether various unlabeled compounds canserve as transport substrates, which has been impossible so far.

Specifically, in one embodiment, the lipid membrane of the presentinvention can be a liposome composition containing a MATE polypeptide.The term “liposome composition” used in the present specification meansa liposome containing a specific substance. A liposome is an artificiallipid membrane also referred to as a vesicle and can be prepared bydispersing suspension of lipids (for example, phospholipids) byvigorously stirring and performing ultrasonication. Liposomes are widelyused for studies and utilized as a cell membrane model or as one ofmeasures for a drug delivery system (DDS).

The liposome composition of the present invention is characterized bycontaining a MATE polypeptide. The liposome composition of the presentinvention may further contain the H⁺-ATPase protein. The H⁺-ATPaseprotein is a protein which actively transports intracellular protons outof the cell and is also referred to as a proton pump. The method forpurifying the proton pump is not particularly limited, andconventionally known methods such as the method described in Moriyama Yet al., J. Biol. Chem. 266, 22141-22146 (1991) can be suitably used.When the transport activity of the MATE polypeptide is determined usingthe liposome composition of the present invention, the activity of amammal-derived MATE polypeptide can be determined even in the absence ofthe H⁺-ATPase protein.

Since a system in which no contaminating protein exists along with theMATE polypeptide can be constructed by using the present invention, itcan be clearly shown whether obtained results are attributable to theMATE polypeptide, and to what extent substrate transport by the MATEpolypeptide is interfered can be found by coexistence of a large numberof proteins can be known.

Furthermore, a system which does not require radiolabeled orfluorescence-labeled substrates can be constructed by using the presentinvention, a wide variety of various chemicals, toxic substances,metabolic biological components, and the like can be analyzed forwhether they are transported by transporter proteins.

Thus, conventional problems can be solved by the present invention, andtransport functions of the MATE polypeptides can be more broadly anddeeply understood. It is needless to say that conventional labeledcompounds can also be used together with the present invention.

Thus, it is sufficient that the liposome composition of the presentinvention comprises at least the polypeptide of the present invention.That is, it should be noted that liposome compositions prepared by knownmethods other than the above-mentioned methods are also encompassed inthe technical scope of the present invention.

(d) Planar Lipid Membrane

In one embodiment, the lipid membrane of the present invention can be aplanar lipid membrane containing a MATE polypeptide. The lipid bilayerhas a membranous structure having two layers of polar lipids (inparticular, phospholipids). The lipid bilayer structure is stabilized asa two-dimensional structure when it is spherical. However, when the endis isolated from water molecules, a planar structure can be formed.Among artificially prepared lipid bilayers used in the presentspecification, a spherical lipid bilayer is referred to as liposome, anda planar lipid bilayer is referred to as planar lipid membrane.

To obtain the planar lipid membrane of this embodiment, a MATEpolypeptide can be embedded in an artificially formed lipid bilayermembrane. Artificial lipid bilayers are used when activities of membraneproteins (for example, channel proteins) are measured in vitro, and allthe preparation methods are known in this field.

Thus, it is sufficient that the planar lipid membrane of the presentinvention comprises at least the polypeptide of the present invention.That is, it should be noted that planar lipid membranes prepared byknown methods other than the above-mentioned method are also encompassedin the technical scope of the present invention.

[3] Utilization of Vector

As described above, a MATE polypeptide can be expressed in an organismor a cell into which the MATE polynucleotide is introduced by using thevector of the present invention. Since the cell membrane is supplied asa transformant or as a part of a transformant, a naturally occurringlipid membrane containing the MATE polypeptide by using the vector ofthe present invention can be obtained. Furthermore, to obtain anartificial lipid membrane, a purified MATE polypeptide (may be anexpression system or a cell-free system) prepared using theabove-described vector can be used.

Thus, the vector of the present invention can be utilized as a tool forpreparation of the lipid membrane of the present invention. That is, thepresent invention provides a method and a kit for preparing a lipidmembrane containing a MATE polypeptide.

The method for preparing a lipid membrane containing a MATE polypeptideof the present invention is characterized by comprising the step ofproducing a MATE polypeptide using a vector containing a MATEpolynucleotide. When a naturally occurring lipid membrane is prepared,the produced MATE polypeptide does not need to be purified. However,when an artificial lipid membrane is prepared, the produced MATEpolypeptide can be used after purification. Those skilled in the art whoread the present specification can easily produce a MATE polypeptideusing a vector containing a MATE polynucleotide.

Furthermore, the kit for preparing a lipid membrane containing a MATEpolypeptide of the present invention is characterized by being providedwith a vector containing a MATE polynucleotide. When a naturallyoccurring lipid membrane is prepared, the above-mentioned vector is arecombinant expression vector. When an artificial lipid membrane isprepared, the above-mentioned vector may be or may not be a recombinantexpression vector.

Thus, it is sufficient that the method and the kit for preparing a lipidmembrane containing a MATE polypeptide of the present invention at leastuse a vector containing a MATE polynucleotide. That is, it should benoted that methods and kits applying known techniques other than theabove-mentioned techniques are also encompassed in the technical scopeof the present invention.

[4] Utilization of Lipid Membrane

The present invention further provides utilization of theabove-mentioned lipid membrane. In the present specification,utilization of lipid membranes will be explained with reference to atransformant and a liposome composition as examples, but utilization ofthe lipid membrane of the present invention is not limited to theseexamples.

(a) Utilization of Transformant Expressing MATE Polypeptide

When the MATE1 polypeptide was expressed in the HEK293 cell,H⁺-dependent transport of tetraethylammonium (TEA) and1-methyl-4-phenylpyridinium (MPP) occurred. The substrate specificity ofMATE1 was similar to that of H⁺-dependent organic cation transportersthat exist in the kidneys or the liver. Thus, MATE1 was found to be amultifunctional OC transporter that excretes organic cations (OCs)directly into the urine or the bile, which had been long searched.

As described above, a MATE polypeptide has a transporter activity in acell membrane, more specifically, a transporter activity (transportactivity) for transporting organic cations (OCs) via a cell membrane.The present invention provides a method and a kit for further screeningfor a substrate, i.e., a target of this transport activity.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned transformanttogether with tetraethylammonium (TEA) or 1-methyl-4-phenylpyridinium(MPP). In the above-mentioned step, if the uptake amount of TEA or MPPinto the above-mentioned transformant is changed in the presence orabsence of a candidate substrate, that is, transport of TEA or MPP isinhibited by the existence of the candidate substrate, it can bedetermined that the candidate substrate is a novel substrate of the MATEpolypeptide.

As demonstrated in the examples described later, cimetidine, quinidine,verapamil, nicotine, corticosterone, Rhodamine 123, testosterone,melatonin, progesterone, androsterone, quercetin, Rhodamine 6G,chloroquine, quinine, pyrimethamine, chlorpromazine, berberine,cisplatin, propranolol, papaverine, and thiamin serve as substrates ofMATE polypeptides in addition to tetraethylammonium (TEA) and1-methyl-4-phenylpyridinium (MPP) in the screening method of the presentinvention. That is, these compounds are transported by MATEpolypeptides.

Thus, those skilled in the art who read the present specification easilyunderstand that one or more of the above-mentioned compounds instead ofTEA or MPP may be used as criteria for determining whether transport ofthe compound(s) is inhibited or not in the screening method of thepresent invention. When used in the present invention, these compoundsare preferably labeled so that they can be detected. Preferred examplesof labels include, but are not limited to, radiolabel.

The screening kit of the present invention is characterized by beingprovided with the above-mentioned transformant. In a preferredembodiment, it is preferable that the screening kit of the presentinvention is further provided with tetraethylammonium (TEA) or1-methyl-4-phenylpyridinium (MPP). In the above-mentioned step, if theuptake amount of TEA or MPP by the above-mentioned transformant ischanged in the presence or absence of a candidate substrate, that is,transport of TEA or MPP is inhibited by the existence of the candidatesubstrate, it can be determined that the candidate substrate is a novelsubstrate of the MATE polypeptide. Furthermore, as described above,instead of TEA or MPP, one or more of cimetidine, quinidine, verapamil,nicotine, corticosterone, Rhodamine 123, testosterone, melatonin,progesterone, androsterone, quercetin, Rhodamine 6G, chloroquine,quinine, pyrimethamine, chlorpromazine, berberine, cisplatin,propranolol, papaverine, and thiamin can be used as criteria fordetermining whether the transport is inhibited or not.

The present invention provides further uses of a transformant expressinga MATE polypeptide. In one aspect, the present invention provides amethod and a kit for screening for a chemical that regulates excretionof a chemical and/or a waste. In another aspect, the present inventionprovides a method and a kit for testing a chemical for nephrotoxicityand/or hepatotoxicity. In yet another aspect, the present inventionprovides a method and a kit for measuring amounts of transport,secretion, accumulation, or excretion of many biological components (inparticular, biological components with high hydrophobicity), such asabsorption or excretion of monoamines, volatile organic cations, andnicotine, secretion, absorption, or excretion of melatonin, steroidhormones, sex hormones, and related formulations thereof, concentrationsof plant alkaloids or phenols in a plant body, as well as a method and akit for screening for a chemical that regulates transport, secretion,accumulation, or excretion thereof. In any case, the present inventionis characterized by using a transformant expressing a MATE polypeptideand preferably utilizes a substrate of a MATE polypeptide. Furthermore,since what compound binds to a MATE polypeptide existing in a cellmembrane can be investigated by using the screening kit of the presentinvention, an inhibitor or an activity enhancer for a MATE polypeptidecan be screened for.

Since the entity of transporters is unknown, various drugs could not betested so far. Chemicals that inhibit the transporter of the presentinvention may cause long-term retention thereof in the body and hencevarious long-term toxicities. Therefore, effects of chemicals on thistransporter need to be tested beforehand when the chemicals arecommercially produced.

To excrete a chemical or a toxin out of the body (urine and/or feces),these substances need to pass through many cells via many kinds oftransporters. The transporter of the present invention is responsiblefor the final stage of such excretion.

The present invention established a cultured cell line constantlyexpressing a novel transporter existing at the apical site (site incontact with primitive urine) of the renal tubules in the kidneys or themicro bile duct in the liver (site at which a bile is excreted) usingmany unspecified organic cations as substrates. This cell line can beused with an assay system for testing transport (excretion) of variousdrugs, agricultural chemicals, and the like.

The method and the kit of the present invention has been explained usinga transformant expressing a MATE polypeptide, but a method furthercomprising the step of preparing a transformant expressing a MATEpolypeptide and a kit further provided with a tool for preparing atransformant expressing a MATE polypeptide also belong to the technicalscope of the present invention.

(b) Utilization of Liposome Composition containing MATE Polypeptide

As explained in detail in the examples, when a MATE1 polypeptide isexpressed in the HEK293 cell, H⁺-dependent transport oftetraethylammonium (TEA) and 1-methyl-4-phenylpyridinium (MPP) occurred.Furthermore, H⁺-dependent transport of tetraethylammonium (TEA) wasconfirmed in a liposome composition containing a MATE1 polypeptide. Thesubstrate specificity of MATE1 was similar to those of H⁺-dependentorganic cation transporters existing in the kidneys or the liver. Thus,it was revealed that MATE1 was a multifunctional OC transporter whichexcretes organic cations (OCs) directly into the urine or the bile,which has been searched over a long period.

As described above, a MATE polypeptide has a transporter activity in acell membrane, more specifically, a transporter activity (transportactivity) for transporting organic cations (OCs) via a cell membrane.The present invention provides a method and a kit for screening for atarget substrate of such a transport activity.

The screening method of the present invention is characterized bycomprising the step of incubating the above-mentioned liposomecomposition together with tetraethylammonium (TEA) or1-methyl-4-phenylpyridinium (MPP). When the uptake amount of TEA or MPPinto the above-mentioned liposome composition is changed in the presenceor absence of a candidate substrate in the above-mentioned step, thatis, transport of TEA or MPP is inhibited by the existence of thecandidate substrate, it can be determined that the candidate substrateis a novel substrate of the MATE polypeptide.

As demonstrated in the examples described later, cimetidine, quinidine,verapamil, nicotine, corticosterone, Rhodamine 123, testosterone,melatonin, progesterone, androsterone, quercetin, Rhodamine 6G,chloroquine, quinine, pyrimethamine, chlorpromazine, berberine,cisplatin, propranolol, papaverine, and thiamin serve as substrates ofMATE polypeptides in addition to tetraethylammonium (TEA) and1-methyl-4-phenylpyridinium (MPP) in the screening method of the presentinvention. That is, these compounds are transported by MATEpolypeptides.

Thus, in the screening method of the present invention, those skilled inthe art who read the present specification easily understand that one ormore of the above-mentioned compounds can be used instead of TEA or MPPfor criteria to determine whether transport thereof is inhibited or not.When used in the present invention, these compounds may be labeled sothat they can be detected. Preferred examples of the label include, butare not limited to, radiolabel and fluorescence label.

The screening kit of the present invention is characterized by beingprovided with the above-mentioned liposome composition. In a preferredembodiment, it is preferable that the screening kit of the presentinvention is further provided with tetraethylammonium (TEA) or1-methyl-4-phenylpyridinium (MPP). In the above-mentioned step, if theuptake amount of the above-mentioned liposome composition by TEA or MPPis changed in the presence or absence of a candidate substrate, that is,TEA or MPP transport is inhibited by the existence of the candidatesubstrate, it can be determined that the candidate substrate is a novelsubstrate of the MATE polypeptide. Furthermore, as described above, oneor more of cimetidine, quinidine, verapamil, nicotine, corticosterone,Rhodamine 123, testosterone, melatonin, progesterone, androsterone,quercetin, Rhodamine 6G, chloroquine, quinine, pyrimethamine,chlorpromazine, berberine, cisplatin, propranolol, papaverine, andthiamin can be used instead of TEA or MPP for criteria to determinewhether transport thereof is inhibited or not.

The present invention further provides further uses of a liposomecomposition containing a MATE polypeptide. In one aspect, the presentinvention provides a method and a kit for screening for a chemical thatregulates excretion of a chemical and/or a waste. In another aspect, thepresent invention provides a method and a kit for testing a chemical fornephrotoxicity and/or hepatotoxicity. In yet another aspect, the presentinvention provides a method and a kit for measuring transport,secretion, accumulation, and excretion of many biological components (inparticular, biological components with high hydrophobicity), such asabsorption or excretion of monoamines, volatile organic cations, andnicotine, secretion, absorption, or excretion of melatonin, steroidhormones, sex hormones, and related formulations thereof, andconcentration of plant alkaloids or phenols in a plant body, as well asa method and a kit for screening for a chemical that regulatestransport, secretion, accumulation, and excretion thereof. In any case,the present invention is characterized by using a liposome compositioncontaining a MATE polypeptide and preferably utilizes a substrate of aMATE polypeptide. Furthermore, since what compound binds to a MATEpolypeptide existing in a cell membrane can be investigated by using thescreening kit of the present invention, an inhibitor or an activityenhancer for a MATE polypeptide can be screened for.

Since the entity of transporters is unknown, various chemicals could notbe tested so far. Chemicals that inhibit the transporter of the presentinvention may cause long-term retention thereof in the body and hencevarious long-term toxicities. Therefore, effects of chemicals on thistransporter need to be tested beforehand when the chemicals arecommercially produced.

To excrete chemicals or toxins out of the body (urine and/or feces),these substances need to pass through many cells via many kinds oftransporters. The transporter of the present invention is responsiblefor the final stage of such excretion.

The present invention established a liposome composition containing anovel transporter existing at the apical site (site in contact withprimitive urine) of the renal tubules in the kidneys or the micro bileduct in the liver (site at which a bile is excreted) using manyunspecified organic cations as substrates. This liposome composition canbe used with an assay system for testing transport (excretion) ofvarious drugs, agricultural chemicals, and the like.

The method and the kit of the present invention have been explainedusing a liposome composition containing a MATE polypeptide, but a methodfurther comprising the step of preparing a liposome compositioncontaining a MATE polypeptide and a kit further provided with a tool forpreparing a liposome composition containing a MATE polypeptide alsobelong to the technical scope of the present invention.

[5] Oligonucleotides and Utilization thereof.

The present invention provides a polynucleotide consisting of thenucleotide sequence of SEQ ID NO: 1, 3, 5, 7, or 21 or a fragment of amutant thereof, or an oligonucleotide consisting of a complementarysequence thereof.

The oligonucleotide of the present invention means a fragment of atleast 12 continuous nucleotides, preferably at least 15 nucleotides,more preferably at least 20 nucleotides, yet more preferably at least 30nucleotides, yet more preferably at least 40 nucleotides in length inthe nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, or 21 or acomplementary sequence thereof. In one embodiment, the oligonucleotideof the present invention can be a DNA fragment based on SEQ ID NO: 1, 3,5, 7, or 21. Since the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, or21 is provided with reference to the present specification, thoseskilled in the art can easily prepare a DNA fragment based on SEQ ID NO:1, 3, 5, 7, or 21. For example, restriction endonuclease digestion orultrasonic shearing can be easily utilized to prepare fragments ofvarious sizes. Alternatively, such fragments can be preparedsynthetically. In another embodiment, the oligonucleotide of the presentinvention can be an oligonucleotide consisting of the nucleotidesequence of any one of SEQ ID NOS: 11 to 18 or a complementary sequencethereof.

The oligonucleotide of the present invention can be used to prepare thepolypeptide of the present invention as a primer for polymerase chainreaction (PCR). Furthermore, the oligonucleotide of the presentinvention can be used for northern blot analysis or as a PCR primer todetect mRNA expression of a target gene in a specific tissue.Specifically, an organism or a tissue expressing a MATE polypeptide canbe easily detected by utilizing the oligonucleotide of the presentinvention as a hybridization probe for detecting a polynucleotide codingfor a MATE polypeptide or a primer for amplifying a polynucleotidecoding for a MATE polypeptide. Furthermore, since intensity ofexpression of a polynucleotide coding for a MATE polypeptide can beconfirmed by using the polynucleotide or the oligonucleotide of thepresent invention, a disease or a disorder attributable to abnormalsubstance transport can be diagnosed.

That is, the present invention further provides a diagnosis method and adiagnosis kit using the above-mentioned oligonucleotide. As describedabove, the oligonucleotide of the present invention hybridizesspecifically with a polynucleotide coding for (MATE polynucleotide) apolypeptide which has the “MATE activity,” that is, a transporteractivity in a cell membrane (MATE polypeptide). Therefore, a disease ora disorder attributable to abnormal substance transport can be diagnosedby detecting the existence or absence of a MATE polynucleotide in eachtissue of an organism by using the oligonucleotide of the presentinvention. Specifically, the expression level of a MATE polynucleotidein a biological sample (in particular, specimen sample of a tissue,cells or a body fluid obtained from specimen) can be obtained byreacting mRNA prepared from the biological sample collected from anorganism tissue by biopsy or the like with the oligonucleotide of thepresent invention.

It is sufficient that the kit for diagnosing a disease attributable toabnormal substance transport involving the MATE polypeptide of thepresent invention is provided with at least the oligonucleotide of thepresent invention. This kit may be further provided with a reagent fordetecting this oligonucleotide, if necessary. Examples of substancestransported by MATE polypeptides include, but are not limited to,tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine,quinidine, verapamil, nicotine, corticosterone, Rhodamine 123,testosterone, melatonin, progesterone, androsterone, quercetin,Rhodamine 6G, chloroquine, quinine, pyrimethamine, chlorpromazine,berberine, cisplatin, propranolol, papaverine, and thiamin.

In other words, an object of the present invention is to provide theoligonucleotide of the present invention and utilization thereof, butnot the oligonucleotide preparation methods and the like specificallydescribed in the present specification. Therefore, it should be notedthat oligonucleotides obtained by methods other than the above-mentionedmethods also belong to the scope of the present invention.

[6] Antibody and Utilization Thereof.

The present invention provides an antibody specifically binding to aMATE polypeptide. In one embodiment, the antibody of the presentinvention is characterized by binding specifically to the hMATE1polypeptide or the mMATE1 polypeptide. The antibody of this embodimentis preferably elicited by a peptide antigen consisting of the amino acidsequence of SEQ ID NO: 19 or a peptide antigen consisting of the aminoacid sequence of SEQ ID NO: 20, but the antibody production method isnot limited to these methods.

The term “antibody” used in the present specification meansimmunoglobulin (IgA, IgD, IgE, IgG, IgM, or Fab fragment, F(ab′)₂fragment, or Fc fragment thereof), and examples thereof include, but arenot limited to, polyclonal antibodies, monoclonal antibodies, singlechain antibodies, anti-idiotype antibodies, and humanized antibodies.The antibody of the present invention can be useful for selection of abiological material expressing a MATE polypeptide and is useful foridentification of the expression site.

The term “antibody binding specifically to a MATE polypeptide” used inthe present specification means a complete antibody molecule or anantibody fragment (for example, Fab or F(ab′)₂ fragment) that can bindspecifically to a MATE polypeptide. Fab, F(ab′)₂, and other fragments ofthe antibody of the present invention are typically produced by cleavageby protein degradation using an enzyme such as papain (generates Fabfragment) or pepsin (generates F(ab′)₂ fragment). Alternatively, a MATEpolypeptide binding fragment can be produced by application ofrecombinant DNA techniques or synthetic chemistry.

Thus, it is sufficient that the antibody of the present invention has atleast an antibody fragment (for example, Fab or F(ab′)₂ fragment) thatrecognizes the above-mentioned peptide antigen. That is, it should benoted that immunoglobulins comprising an antibody fragment thatrecognizes the above-mentioned peptide antigen and Fc fragment ofanother antibody molecule are also encompassed in the scope of thepresent invention.

The present invention further provides a peptide antigen eliciting anantibody that can detect a mammal MATE polypeptide. That is, the peptideantigen of the present invention is useful in a method and a kit forproducing an antibody effective for immunoassay. The term “immunoassay”used in the present specification means an assay performed utilizing animmunological binding reaction based on antigen-antibody reaction.Examples of the assay utilizing an immunological binding reactioninclude antibody assays such as immunohistochemistry, immunoelectronmicroscopy, western blot, immunosedimentation assay (immunoprecipitationassay), sandwich ELISA assay, radioactive immunoassay, andimmunodiffusion assay, affinity chromatography, and so forth.

The above-mentioned peptide antigen may be chemically synthesized orisolated from a natural supply source as with MATE polypeptides, orobtained utilizing recombinant expression (for example, GST fusionprotein).

Those skilled in the art who read the present specification easilyunderstand that antibody production methods and kits comprising the stepof eliciting an antibody using the above-mentioned peptide antigen arealso encompassed in the scope of the present invention. In a method forproducing the antibody of the present invention, a complex of theabove-mentioned polypeptide and an adjuvant may be used as an antigen.

The present invention further provides a diagnosis method and adiagnosis kit using the above-mentioned antibody. As described above,the antibody of the present invention has the “MATE activity,” that is,binds specifically to a polypeptide which has a transporter activity(MATE polypeptide) in a cell membrane. A disease or a disorderattributable to abnormal substance transport can be diagnosed bydetecting existence or absence of a MATE polypeptide in each tissue ofan organism using the antibody of the present invention. Specifically,the expression level of a antigen polypeptide binding to an antibodybinding specifically to a MATE polypeptide (i.e., a MATE polypeptide) ina biological sample can be obtained by reacting a biological sample (inparticular, specimen sample of a tissue, cells or a body fluid obtainedfrom specimen) collected from an organism tissue by biopsy or the likeand this antibody.

It is sufficient that the kit for diagnosing a disease attributable toabnormal substance transport involving the MATE polypeptide of thepresent invention is provided with at least an antibody bindingspecifically to a MATE polypeptide. The antibody is preferably anantibody for mouse or human MATE1 or MATE2. This kit may be furtherprovided with a reagent for detecting this antibody, if necessary.Examples of substances transported by MATE polypeptides include, but arenot limited to, tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium(MPP), cimetidine, quinidine, verapamil, nicotine, corticosterone,Rhodamine 123, testosterone, melatonin, progesterone, androsterone,quercetin, Rhodamine 6G, chloroquine, quinine, pyrimethamine,chlorpromazine, berberine, cisplatin, propranolol, papaverine, andthiamin.

In other words, an object of the present invention is to provide anantibody that recognizes the MATE polypeptide of the present inventionand utilization thereof, but not individual immunoglobulin types (IgA,IgD, IgE, IgG, or IgM), the chimera antibody production method, thepeptide antigen production method, and so forth specifically describedin the present specification. It should be noted that antibodiesobtained by methods other than the above-mentioned methods also belongto the scope of the present invention.

[7] Knockout Animal

A knockout animal is a gene deficient-animal obtained by destroying aspecific gene. A knockout animal (in particular, mouse) is constructedas an animal having the target destroyed gene homozygously by performinggene destruction in a totipotent embryonic stem cells (ES cells),screening for ES cells in which the target gene is destroyed, preparinga chimeric animal using these cells and a mouse embryo, and mating twoor more generations of animals from the chimeric animal havingreproductive cells derived from ES cells. Knockout animal is a veryeffective technique for constructing a novel laboratory animal, inparticular, a disease model animal.

The present invention provides a knockout animal in which the MATE geneis destroyed. The knockout animal of the present invention is preferablya mouse. Since the knockout animal preparation method is known in thisfield, those skilled in the art can easily prepare a MATE gene-knockoutanimal based on the information of the MATE gene provided by the presentspecification.

By using the knockout animal of the present invention, a chemical thatregulates substance transport across a cell membrane or a substrate of apolypeptide which has a transporter activity in a cell membrane can bescreened for. Furthermore, a chemical can be tested for nephrotoxicityand/or hepatotoxicity by using the knockout animal of the presentinvention. Furthermore, the knockout animal of the present invention cangreatly contribute to treatment of a disease attributable to abnormalsubstance transport across a cell membrane as a model animal of thedisease.

The present invention will be explained more specifically with referenceto the following examples. However, the scope of the present inventionshould not be limited to these examples.

EXAMPLES 1: Materials and Methods

[1-1. Cloning of cDNA]

Cloning was performed by RT-PCR using total RNA obtained by extractingthe cDNA of human MATE1 (hMATE1: accession number NP-060712) from thehuman brain. After reverse transcription reaction, the cDNA solution wasdiluted 10-fold and added to a PCR buffer containing 0.6 mM dNTPs (150μM each dNTP), 25 pmol of the primer pair, and 1.5 units of Ampli Taqpolymerase (Perkin Elmer). PCR amplification was performed as follows:denaturation at 94° C. for 30 seconds, annealing at 56° C. for 30seconds, and elongation at 72° C. for 1 minute. The amplificationproduct (1804 base pairs) was analyzed by agarose gel electrophoresis.The primers were prepared based on Genbank accession number AK001709(sense primer, 5′-ggccggtacccgcgagtcacatggaagctc-3′; antisense primer,5′-cacttctagacctgtgaattgtgtgtaagc-3′). The amplified DNA fragment wasdigested with restriction enzymes (KpnI and XbaI) and inserted intopBluescriptKS(+). The gene sequence of human MATE1 was compared with thehuman genome sequence, and it was confirmed that there was no error.

Similarly, human MATE2 (hMATE2: accession number NP-690872) was clonedusing a primer pair (sense,5′-agtcgaattccaccatggacagcctccaggacacagtgg-3′; antisense,5′agctctcgagctagtgcctggtggctaggatcctgac-3′), mouse MATE1 (mMATE1:accession number AAH31436) using a primer pair (sense,5′-cgccggtaccaccatggaacgcacggagga-3′; antisense,5′-agacagtttattgctgtcctttggacggat-3′), and mouse MATE2 (mMATE2:accession number XP_(—)354611) using a primer pair (sense,5′-caccgaattcatggagccggccgaggaca-3′; antisense,5′-cgtactcgagttagccacggtcattgaaa-3′).

[1-2. Point Mutagenesis]

A point mutation (E273Q) was introduced into human MATE1 according tothe method in Non-patent Document 12 using an oligonucleotide primer(5′-ggcccaccactgcatgcacagcatgagc-3′).

[1-3. Northern Blot Analysis]

Human and mouse multitissue northern blots (MTN) were purchased fromClontech. The N terminal region (nt10-601; 592 bp) of human MATE1, the Cterminal region (nt1412-1712; 301 bp) of human MATE2, the C terminalregion (nt1336-1599; 264 bp) of mouse MATE1, and the C terminal region(nt1087-1648; 562 bp) of mouse MATE2, which were obtained by PCRamplification, were labeled with ³²P-dCTP using a DNA labeling kit(Boehringer Mannheim) and used as probes in northern blot. Hybridizationwas performed using Express Hyb hybridization buffer (Clontech) at 68°C. for 1 hour, and the product was washed at 50° C.

[1-4. Preparation of Antibody]

A rabbit polyclonal antibody specific to human MATE1 or mouse MATE1 wasprepared using a GST fusion protein obtained by fusing the 461st to546th amino acids of human MATE1 or the P495th to Q532nd amino acids ofmouse MATE1 with GST as an antigen.

[1-5. Western Blot]

A human tissue sample was purchased from Cosmo Bio. A membrane fractionwas prepared from 1 g of mouse tissue. Each tissue was suspended in abuffer comprising 20 mM MOPS-Tris (pH 7.0), 0.3 M sucrose, 5 mM EDTA,and protease inhibitors (10 μg/ml each pepstatin A, leupeptin, antipain,and chymostatin) and then homogenized. The nuclei were removed, and thenthe suspension was centrifuged at 100,000×g for 1 hour. The supernatantwas removed, and the precipitates were suspended in the above-mentionedbuffer. A buffer containing 1% SDS and 10% β-mercaptoethanol was added,then a human membrane fraction (100 μg) and a mouse membrane fraction(200 μg) were used as samples for electrophoresis. Western blot wasperformed according to a usual method (refer to Non-patent Document 13).

[1-6. Immunohistological Staining]

A human paraffin tissue section was purchased from Biochain.Immunohistochemical analysis was performed according to Non-patentDocument 13 using the HRP-DAB method or the indirect fluorescenceantibody microscopy method. The primary antibody reaction was performedin 0.5% bovine serum albumin (BSA) using 1000-fold diluted or 1 μg/mlprimary antibody at room temperature for 1 hour. The samples wereanalyzed using Olympus BX60 Microscope or Olympus FV300 Confocal LaserMicroscope.

[1-7. Immunoelectron Microscopy]

Gold colloid silver-sensitized electron microscopy was performedaccording to Non-patent Document 13. Physiological saline was perfusedfrom the heart of a mouse anesthetized with ether, and then 0.1 M sodiumphosphate buffer (pH 7.4) in which 4% paraformaldehyde was dissolved wasrefluxed. The kidney was isolated and washed with PBS. A tissueimpregnated with a PBS solution containing 30% sucrose was sectioned(6-mm thickness), placed on a silanated slide glass, and embedded in anOTC compound (Sakura FineTek). The sections were incubated in 0.1 Msodium phosphate buffer (pH 7.4) containing 0.25% saponin and 5% BSA for30 minutes and then blocked using a blocking solution containing 0.005%saponin, 10% BSA, 10% goat serum, and 0.1% cold water fish gelatin(Sigma). Then, the sections were incubated overnight at 40 together withthe rabbit anti-mouse MATE1 antibody 1000-fold diluted with the blockingsolution. The sections were adequately washed with a buffer containing0.005% saponin, then incubated in a blocking solution containing goatanti-rabbit IgG gold colloid (diameter of a gold particle, 1.4 mm) for 2hours, washed 6 times with the buffer, and then immobilized using 1%glutaraldehyde for 10 minutes. The sections were further washed, thentreated with a silver sensitization kit (HQ silver Nanoprobes) at roomtemperature for 5 minutes, then immobilized for 90 minutes using 0.5%osmium tetraoxide. Ultrathin sections were double-stained with uraniumacetate and lead citrate and analyzed using Hitachi H-7100 ElectronMicroscope.

[1-8. Determination of Transport Activity]

According to Non-patent Document 14, HEK293 cells were cultured in aDulbecco's modified Eagle medium containing 10% bovine fetus serum,penicillin, and streptomycin at 37° C. under 5% CO₂. The pcDNA3.1/hMATE1plasmid obtained by subcloning the cDNA coding for human MATE1 or mouseMATE1 in an expression vector pcDNA3.1(+) (Invitrogen) was transfectedinto the HEK293 cells cultured for 24 hours using TransIT reagent(Mirus) (cell count: 1.5×10⁶ cells/10-cm dish). Cells cultured for 2days were recovered and suspended in an activity determination buffer(pH 8.0) comprising 125 mM sodium chloride, 4.8 mM potassium chloride,5.6 mM D-glucose, 1.2 mM calcium chloride, 1.2 mM potassium dihydrogenphosphate, 1.2 mM magnesium sulfate, and 25 mM tricine. Cells wereincubated at 37° C. for 5 minutes, 50 μM RI-labeled TEA (5 kBq/assay)(PerkinElmer Life Science, Inc.) was added, and measurement of thetransport activity was initiated. 200 μl each of the reaction mixturesfor activity determination was recovered at a predetermined time pointand filtered through a 0.45-μm HA membrane filter (Millipore), andradioactivity remaining on the filter was determined.

[1-9. Determination of Nicotine Transport Activity]

The activity at pH 8.0 was determined using a buffer comprising 125 mMsodium chloride, 4.8 mM potassium chloride, 5.6 mM D-glucose, 1.2 mMcalcium chloride, 1.2 mM potassium dihydrogen phosphate, 1.2 mMmagnesium sulfate, and 25 mM tricine. The activity at pH 7.0 was furtherdetermined using a buffer comprising 125 mM sodium chloride, 4.8 mMpotassium chloride, 5.6 mM D-glucose, 1.2 mM calcium chloride, 1.2 mMpotassium dihydrogen phosphate, 1.2 mM magnesium sulfate, and 25 mMMOPS-NaOH.

Radioactive nicotine (100 nCi, 2 μM) was added to the above-mentionedactivity determination buffer prepared in the above-mentioned 8, inwhich human MATE1 expression HEK293 cells (8×10⁵ cells) were suspendedat a final volume of 200 μl. Cells were incubated at 37° C. for 5minutes, and the suspension was centrifuged at 5000 rpm at 37° C. Thecells and the supernatant were fractionated, and uptake of nicotine intocells was measured by determining radioactivity contained each of themwith a liquid scintillation counter.

[1-10. Purification of Proton Pump Protein]

The F₀F₁ protein, a proton pump, was prepared according to theprocedures described in Moriyama Y et al., J. Biol. Chem. 266,22141-22146 (1991).

Escherichia coli DK8 harboring plasmid pBWU13 expressing a large amountof F₀F₁ was cultured with Tanaka medium (34 mM monopotassium phosphate,64 mM dipotassium phosphate, 20 mM ammonium sulfate, 0.3 mM magnesiumchloride, 1 μM iron sulfate, 1 μM calcium chloride, 1 μM zinc chloride,100 μg/ml isoleucine, 100 μg/ml valine, 2 μg/ml thiamin) containing 0.5%glycerol, and then bacterial cells were recovered. All the preparationsthereafter were performed at 4° C.

About 10 g of bacterial cells (DK8/pBWU13) were suspended in 40 ml ofmembrane preparation buffer (at 4° C. 50 mM Tris-HCl [pH 8.0], 2 mMmagnesium chloride, 0.5 mM EDTA, 1 mM PMSF, 1 μg/ml leupeptin, 1 μg/mlpepstatin A, 10% [v/v] glycerol, 1 mM DTT), and cells were disruptedwith a French press (1,500 kg/cm²). The disrupted cell suspension wascentrifuged at 17,000×g for 10 minutes, and the obtained supernatant wasfurther centrifuged at 210,000×g for 1 hour 20 minutes. The obtainedmembrane vesicle precipitates were suspended in the F₀F₁ preparationbuffer (20 mM MOPS/NaOH [pH 7.0], 1 mM magnesium sulfate, 1 mM DTT, 1 mMPMSF, 0.8% octyl glucoside) and centrifuged again. 60 mg of the membranevesicle prepared as the precipitate was suspended in 3 ml of F₀F₁preparation buffer containing 2% octyl glucoside to solubilize F₀F₁. Thesolubilized solution was centrifuged at 260,000×g for 30 minutes, andF₀F₁ was recovered from the supernatant fraction. The recovered F₀F₁ waspurified by centrifugation with 10 to 30% (w/v) glycerol densitygradient (330,000×g for 5 hours). The glycerol density gradient wasprepared with an F₀F₁ preparation buffer containing 1% octyl glucoside.After density gradient centrifugation, the resultant was isolated anddivided into 10 fractions from the bottom of the centrifuge tube, andthe first four fractions were recovered as F₀F₁ and stored at −80° C.

Results [2-1. Gene Structure and Expression of Human MATE1]

Mammalian analogs of the MATE family, multidrug efflux transporters inbacteria, were searched on a database. As a result, it was found thatthree genes coding for analogs of the MATE family exist on the human17th chromosome, and these genes were designated as hMATE1 (accessionnumber NP-060712), hMATE2 (accession number NP-690872), and hMATE3 (FIG.1). The MATE3 gene was a novel gene.

The putative amino acid sequences of the above-mentioned genes hadhomologies of 19.8% and 18.6% with NorM, a Na⁺-dependent multidrugefflux transporter of Vibrio bacteria, which is a prototype of the MATEfamily (refer to Non-patent Document 15) (FIG. 2). In FIG. 2, anasterisk indicates identical amino acids, and the putative transmembraneregion was surrounded in a square. E273 is glutamic acid, which is anamino acid important for the transport activity. Human MATE1 is aprotein having 12 transmembrane regions according to the hydrophobicityplot (FIG. 3).

As a result of northern blot analysis of human tissues, the human MATE1gene was found to be expressed as a 4.1-kb transcription productprimarily in the kidneys, the liver, and the skeletal muscles.Furthermore, the human MATE2 gene was expressed as a 3.2-kbtranscription product in the kidneys, but not expressed in other tissues(FIG. 4( a)).

[2-2. Localization of Human MATE1 in Kidneys and Liver]

The inventors of the present invention considered that human MATE1 is anH⁺-dependent OC transporter at the protein level and investigatedexpression and localization thereof. As a result of western blotanalysis using a specific antibody against the C terminal peptide ofhuman MATE1, a band of 62 kDa, which is equal to the putative molecularweight size, was detected in human kidney membrane fractions (FIG. 4(b)). As a result of immunohistochemistry by horseradish peroxidase(HRP)-DAB staining, the human MATE1 protein was found to be expressed inepidermal cell sites of the proximal renal tubule and the distal renaltubule in the kidneys (FIG. 4( c)) and particularly in hepatocytes atthe bile duct site (FIG. 4( d)).

[2-3. Expression and Localization of Mouse MATEL]

MATE family analogs in mice were obtained, and the MATE family inmammals was further analyzed. It was found that two genes coding for themouse MATE family analogs exist on the 11th mouse chromosome next toeach other, and these genes were designated as mMATE1 (accession numberAAH31436) and mMATE2 (accession number XP_(—)354611) (FIG. 5). Theseputative amino acid sequences had homologies of 78.1% and 38.1%,respectively, with human MATE1 (FIG. 6).

As a result of the northern blot analysis of mouse tissues, it was foundthat the mouse MATE1 gene is expressed primarily in the kidneys, theliver, and the heart as a 3.8-kb transcription product. Furthermore, themouse MATE2 gene was found to be expressed particularly in the testicleas a 3.3-kb transcription product (FIG. 7( a)).

As a result of western blot analysis using a specific antibody againstmouse MATE1, a band of 53 kDa, which was equal to the putative molecularweight size, was detected in the kidneys and the liver in mice (FIG. 7(b)). As a result of immunohistochemistry by horseradish peroxidase(HRP)-DAB staining, reactions of the mouse MATE1 protein were intenselydetected in the collecting tubule and the proximal renal tubule of thekidney (FIG. 7( c)), particularly, around the periphery of the Henle'sloop (FIG. 7( d)). Furthermore, although at a weak level, reactions ofthe mouse MATE1 protein were clearly detected in the distal renal tubuleand the glomerulus as well (FIG. 7( c)).

As a result of the immunoelectron microscope analysis, it was confirmedthat mouse MATE1 was localized in the renal proximal tubular brushborder membrane (FIG. 8( a)). In the liver, mouse MATE1 existed in thecapillary bile duct and was distributed in the bile duct surface (FIG.8( b)).

These results revealed that mammal MATE1 was expressed primarily in thekidneys (particularly in the renal proximal tubular brush bordermembrane) and the liver (capillary bile duct). This finding isconsistent with the H⁺/OC exchange transport activity known so far(refer to Non-patent Documents 5 to 7).

[2-4. MATE1 is Involved in OC Exchange Transport without GeneratingProton-Dependent Potential Gradient]

To clarify whether MATE1 has the proton-coupled OC exchange transportactivity, pH-dependent OC transport via a biomembrane was analyzed inthe HEK293 cell expressing human MATE1. According to this method, OCtransport in the lumen can be analyzed as a classic cell uptake activity(refer to Non-patent Document 14). Cells expressing human MATE1exhibited a time-dependent transport activity against TEA, arepresentative substrate of a proton-coupled OC transporter (FIGS. 9( a)and (b)). In cells expressing wild type MATE1, the transport activitywas saturated, and the Km value of TEA was 220 μM (FIG. 9( c)).Furthermore, the transport activity was dependent on pH in cellsexpressing wild type MATE1. The activity was low at pH 6.0 and increasedat higher pH, with the maximum activity at pH 8.0 to 8.5 (FIG. 9( d)).As shown in FIG. 9( e), however, this transport activity did not requiresodium ions. That is, even when membrane depolarization was caused byadding 5 μM valinomycin in the presence of 65 mM potassium chloride, theTEA uptake activity was not affected. Furthermore, the TEA uptakeactivity was inhibited by 60% by ammonium chloride. Furthermore, when pHgradient was eliminated with nigericin (5 μM) in the presence of SF6847(10 μM), a proton conductor, or potassium chloride, the TEA uptakeactivity greatly decreased (FIG. 9( e)).

These results showed that human MATE1 performs H+/TEA exchange transportwithout generating a potential gradient.

[2-5. Inhibition of Transport Activity by Various Compounds]

Using HEK293 cells in which hMATE1 or mMATE1 was expressed, uptake of 50μM R1-labeled tetraethylammonium (TEA) was analyzed at pH 8.0 in thepresence or absence of the compounds at concentrations shown in thetable (Table 1).

TABLE 1 mMATE1 hMATE1 Compounds (mM) % ± S.D. % ± S.D. Control 100.0 ±4.7  100.0 ± 1.9  Cimetidine 0.01 29.3 ± 5.2 44.7 ± 7.4 0.1  3.1 ± 5.1 9.7 ± 8.7 Quinidine 0.01 74.7 ± 9.8 35.0 ± 2.1 0.05 50.3 ± 5.4  5.1 ±8.9 0.1 26.6 ± 7.3  0.0 ± 4.2 Procainamide 0.1 65.7 ± 8.2 62.6 ± 0.8Verapamil 0.1 23.6 ± 9.5  7.7 ± 7.6 Guanidine 0.5 96.0 ± 8.5 93.4 ± 7.6Carnitine 5 71.2 ± 6.1 104.2 ± 6.4  TEA 5 0.0 ± 7.  0.7 ± 1.8 MPP 0.133.1 ± 9.5 67.4 ± 8.4 5  0.0 ± 2.1  0.0 ± 0.3 Nicotine 0.1 91.9 ± 3.163.7 ± 5.0 5 36.7 ± 3.1  5.8 ± 4.3 NMN 1 115.3 ± 8.9  93.5 ± 1.9 Choline5 62.0 ± 8.8 62.7 ± 4.1 Serotonin 0.1 86.9 ± 5.7 67.5 ± 8.0Corticosterone 0.1 50.0 ± 2.5 10.0 ± 6.7 Rhodamine123 0.01  0.5 ± 6.2 5.0 ± 6.4 Quercetin 0.1 47.1 ± 0.1 28.2 ± 3.1 Lactate 10 93.9 ± 3.2103.8 ± 8.8  Succinate 10 95.1 ± 6.3 108.1 ± 4.2  Salicylate 10 92.4 ±4.3 97.8 ± 4.8 Probenecid 1  93.7 ± 11.9 108.5 ± 7.9  Uric acid 1 109.1± 6.4  107.8 ± 2.7  PAH 5 94.7 ± 9.1 110.3 ± 2.7  Testosterone 0.00167.0 ± 8.7 99.6 ± 4.3 0.01 44.7 ± 3.0  64.5 ± 14.7 0.1 11.5 ± 1.1 38.8 ±3.2 Melatonin 0.1 51.4 ± 0.8 85.0 ± 4.0 Progesterone 0.1  9.3 ± 1.6 31.7± 5.6 Androstenedione 0.1  8.6 ± 1.7 36.6 ± 0.9 Rhodamine 6G 0.01  6.8 ±2.0 Chloroquine 0.01 56.9 ± 5.1 Chloroquine 0.1 36.9 ± 1.1 Quinine 0.0130.4 ± 2.8 Pyrimethamine 0.00001 45.2 ± 3.5 0.0001 19.8 ± 1.6Chlorpromazine 0.1 12.2 ± 3.6 Reserpine 0.001 86.3 ± 3.5 0.01 22.8 ± 0.9Quinacrine 0.01 41.6 ± 8.2 Berberin 0.001 69.2 ± 2.1 0.01 20.4 ± 2.4 0.1 4.2 ± 0.9 Rutin 0.1 71.8 ± 3.6 Tocopherol 0.1 78.8 ± 9.6 Thiamine 0.155.7 ± 7.0 1 31.1 ± 3.9 Cisplatin 1 35.6 ± 6.0 Paraquat 1 57.2 ± 6.8Propranolol 0.1 30.1 ± 3.9 Droperidol 0.001  74.1 ± 14.7 Imipramine 0.01 74.7 ± 11.9 Atropine 0.1 74.6 ± 5.5 Pilocarpine 0.1 96.1 ± 0.4Papaverine 0.01 26.8 ± 2.7 Metformin 0.1 120.5 ± 9.4  Amantadine 0.175.5 ± 9.8 Digoxin 0.001 102.5 ± 7.3  Ouabain 0.01 115.9 ± 6.6 Bisphenol A 0.01 113.9 ± 2.1  Catechin 0.1 104.0 ± 4.4 Diethylstilbestrol 0.1 94.9 ± 7.8 Thyroxine 0.1 113.0 ± 4.5  Spermidine0.05  97.0 ± 11.4

Values in the table represent TEA uptake activity percents taking thelevel with addition of no compound as 100%. NMN denotesN-methylnicotinamide. Data are shown as mean±standard deviation of threeto nine experiments. *<0.05, **<0.001.

Whether these compounds can serve as transport substrates can beexamined by measuring uptake of radioactive TEA into cells in thepresence of the above-mentioned compounds. As shown in Table 1, the TEAuptake activity was inhibited by cimetidine, quinidine, verapamil,1-methyl-4-phenylpyridinium (MPP), nicotine, corticosterone, Rhodamine123, testosterone, melatonin, progesterone, androsterone, and quercetin.That is, it was found that these compounds were transported by MATE1. Inparticular, the TEA uptake activity was strongly inhibited bycimetidine, quinidine, and verapamil and mildly inhibited by nicotineand choline. However, the activity was not inhibited bypara-aminobutyric acid or uric acid, organic anions. When MPP known as asubstrate of a proton-coupled OC transporter was used, pH-dependencesimilar to that in use of TEA was observed, and the Km value and Vmaxwere 16 μM and 170 pmol/min/mg protein, respectively. Thus,characteristics of MATE1 totally matched the proton-coupled OC transportactivity in the kidneys predicted so far.

No nicotine transporter has been known at all, but it was found by theexperiment using radioactive nicotine that the MATE1 protein wasfunctioning as a nicotine transporter (FIG. 10). In the figure, data areshown as the mean±standard deviation of three experiments.

Thus, the substrate specificity of MATE1 was clarified in the experimentof competitive inhibition in TEA transport. Furthermore, the results ofthe experiment of competitive inhibition in TEA transport showed resultssimilar to those of the proton-coupled OC transport activity in thekidneys.

3: Construction of Assay System using Liposome Composition

[3-1. Preparation of Baculovirus for hMATE1 Expression]

The hMATE1 cDNA with four base pairs, CACC, added at the 5′ end thereofwas mixed with the TOPO vector, and the mixture was introduced intocompetent cells (DH5a) by the heat shock method. The plasmidpENTER-hMATE1 in which hMATE1 was incorporated was selected usingkanamycin and recovered with QIAprep Spin Miniprep Kit (QIAGEN). ThehMATE1 cDNA in this plasmid was cloned into the expression vectorpDEST10 (INVITROGEN) using LR recombinase (INVITROGEN) forrecombination. The obtained plasmid was selected on an ampicillin mediumand recovered with QIAprep Spin Miniprep Kit (QIAGEN). DH10Bac(INVITROGEN) transformed using this plasmid was selected on a mediumcontaining kanamycin, gentamicin, tetracycline, IPTG(isopropylthiogalactoside), and X-gal(5-bromo-4-chloro-3-indolyl-β-D-galactoside). Since the DH10Bac cell hasthe genomic DNA of baculovirus, cDNA introduced into pDEST10 isautomatically cloned onto the virus genome by a transposon. As a result,colonies in which the galactosidase gene on the virus genome isdestroyed and purified have a white color. Bacmid (recombinant virusgenomic DNA) was recovered from white colonies on this medium by theminiprep method according to the following procedures.

The transformed DH10Bac was suspended in 0.3 ml of solution I (25 mMTris-HCl [pH 8.0], 50 mM glucose, 10 mM ethylenediaminetetraaceticacid), and an equal volume of solution II (0.2 N NaOH, 1% sodiumdodecylsulfate) was added to this suspension. After allowed to stand for5 minutes, 0.3 ml of solution III (3 M potassium acetic acid [pH 5.2])was added to this suspension. This suspension was centrifuged at18,000×g for 10 minutes, and 0.8 ml of isopropyl was added to theobtained supernatant. This solution was allowed to stand on ice for 5minutes and further centrifuged for 15 minutes. The obtainedprecipitates were washed twice with ice-cold 70% ethanol and dried. Thedried precipitates were suspended in 40 μl of TE buffer (Tris-HCl [pH8.0], 1 mM ethylenediaminetetraacetic acid) to obtain a recombinantbacmid solution.

Recombinant baculovirus was prepared according to the followingprocedures. About 3 μl of the prepared bacmid was introduced into sf9insect cells (INVITROGEN) using Cellfectin Reagent (INVITROGEN). The sf9cells into which the bacmid was introduced were cultured in TNM-FHmedium (GIBCO) containing 10% bovine fetus serum, 100 μg/ml penicillin,100 μg/ml streptomycin, and 0.25 μg/ml fungizone. These cells werecultured at 27° C. for 4 to 7 days, the culture supernatant wasrecovered, and recombinant baculovirus was obtained from the culturesupernatant. The sf9 cells were infected with the obtained recombinantbaculovirus again, and these infected cells were cultured in a 70 to75-cm² flask for 4 to 7 days, the culture supernatant was recovered, andvirus was obtained from the culture supernatant at a high concentration.

[3-2. Purification of hMATE1 Polypeptide]

Hi-Five cells (Invitrogen) were cultured in 21 dishes each containing1×10⁷ cells and infected with the hMATE1 expressing virus at MOI=1. Theinfection cells were incubated at 27° C. for 48 hours and recovered. Therecovered cells were suspended in 10 ml of 20 mM Tris-Cl (pH 8.0)containing 100 mM sodium acetate, 10% glycerol, 10 μg/ml leupeptin, and10 μg/ml pepstatin A. This suspension was centrifuged and resuspended in10 ml of the same buffer. The same procedure was repeated (washedtwice). Then, cells suspended in 10 ml of the same buffer were disruptedwith an ultrasonic generator (TOMY UD200). Undisrupted cells werecentrifuged at 2000 rpm for 8 minutes, and the obtained supernatant wasfurther centrifuged at 40,000 rpm for 1 hour (Beckman L-60, 60T1 rotor).The obtained precipitates were suspended in 3 ml of 20 mM MOPS-Tris (pH7.0) containing 2% octyl glycoside, 10% glycerol, 10 μg/ml leupeptin,and 10 μg/ml pepstatin A, and this suspension was allowed to stand onice for 30 minutes. Subsequently, the suspension was centrifuged withTL-100 Ultracentrifuge at 70,000 rpm for 30 minutes, and a solubilizedMATE1 crude sample was obtained as a supernatant. Ni-NTA resin (QIAGEN)was added to this crude sample and incubated at 4° C. for 4 hours. Theresin was washed with 20 ml of 20 mM MOPS-Tris (pH 7.0) containing 1%octyl glycoside, 10% glycerol, 10 μg/ml leupeptin, and 10 μg/mlpepstatin A, and then incubated in 3 ml of 20 mM MOPS-Tris (pH 7.0)containing 1% octyl glycoside, 10% glycerol, 10 μg/ml leupeptin, and 10μg/ml pepstatin A to obtain 1.3 mg of purified hMATE1 polypeptide (FIG.11).

A part of a product from each step of the hMATE1 purification stage (Srepresents 100 μg of solubilized insect cell membrane fraction; W1 andW2 represent 80 μl of supernatant after each wash; E represents 20 μg ofpurified hMATE protein; L represents 20 μg of hMATE proteinreconstituted into a liposome) was subjected to SDS gel electrophoresis,and FIG. 11 shows the results of this CBB-stained gel. FIG. 11 showsthat the target hMATE polypeptide was purified as virtually one singleprotein band.

[3-3. Production of Liposome Composition]

Soybean phospholipid (Sigma type IIS) was suspended in 10 mM MOPS-Tris(pH 7.0) and 0.5 mM DTT (10 mg/ml). This suspension was ultrasonicatedwith a bath-type sonicator, and a uniform solution was dispensed andstored at −80° C.

A part of the stored solution was thawed, and 1 mg of purified hMATE1(800 μl) was added to 150 μl of this solution and mixed vigorously.These mixtures were rapidly frozen at −80° C., maintained for 10minutes, then melted in hands, and then rapidly mixed with 20 ml ofice-cooled 20 mM MOPS-Tris (pH 7.0) containing 0.1 M potassium acetate,5 mM magnesium acetate, and 0.5 mM DTT. This mixture was centrifuged at45,000 rpm for 1 hour, and a reconstituted liposome was obtained as aprecipitate. This reconstituted liposome was suspended in 500 μl ofice-cooled 20 mM MOPS-Tris (pH 7.0) containing 0.1 M potassium acetate,5 mM magnesium acetate, and 0.5 mM DTT and subjected to the transportexperiment.

[3-4. Determination of Transport Activity of MATE Polypeptide]

40 μl of the above-mentioned reconstituted liposome (liposome containinga MATE polypeptide) (corresponding to about 12 μg of protein) wasdispensed, and measurement was initiated by further adding 540 μl ofbuffer (20 mM Tricine-NaOH [pH 8.0], 0.1 M potassium acetate, 5 mMmagnesium acetate) containing 1 mM ¹⁴C-TEA (0.5 μCi)

After a certain time period passed, 150 μl of the reaction mixture wascollected, applied to 1 ml of Terumo syringe filled with Sephadex G50,and immediately centrifuged at 2000 rpm for 1 minute. A predeterminedvolume of a solution eluted from the syringe (containing liposomes) wascollected, and radioactivity was measured with a liquid scintillationcounter (FIG. 12). The extracellular fluid was trapped in a syringe.

FIG. 12 shows changes in transport over time. The magnitude of pHgradient across the liposome membrane can be changed by changing pH ofthe extracellular fluid. As shown in FIG. 12, pH-dependent uptake of TEAwas observed. When no MATE polypeptide, a transporter, existed, almostno radioactivity was detected (background level).

4: MATE1 Functioning as OC Transporter in Final Stage of Excretion

Based on the above results, it can be said that MATE1 is aproton-coupled OC transporter responsible for the final stage of OCexcretion in the kidneys and/or the liver which has been searched for along time so far (FIG. 13). Based on the above-mentioned results, thewhole picture of the mechanism of a transporter that excretes OCs havingtoxicity from an organism can be clarified.

OCs are taken up by an organic cation transporter (OCT1) in the liver orOCT2 in the renal tubules in the kidneys, and it was found that OCstaken up were excreted from cells by a concerted reaction of MATE1 witha P-glycoprotein. It was also found that MATE1 can use variousmetabolites as substrates from the competitive inhibition experiment.

Furthermore, no nicotine transporter has been known among animals,plants, and bacteria, and the present invention revealed for the firsttime that MATE1 is responsible for the function thereof. Furthermore,since no transporter of melatonin or hormones has been known so fareither, it can be said that MATE1 is a clinically very importantprotein. In fact, MATE polypeptides are expressed in a plasma membrane(apical side) of a mouse alveolar epithelial cell or in thecerebrovascular system (FIGS. 14 and 15). Furthermore, it has beenconfirmed that hMATE1 is expressed in human alveolar epithelial cells(FIG. 16).

The MATE polypeptide was found to have functions other than excretion ofwastes in various tissues such as the skin and the pineal body. In theskin, MATE1 is expressed in the perspiratory gland and the sebaceousgland and is involved in percutaneous absorption of chemicals, excretionof substances involved in body odor, and the like (FIG. 17). It wasfound that MATE1 was also expressed in the pineal body, which controlscircadian rhythm, through melatonin secretion (FIG. 18). This indirectlyshows that MATE1 uses melatonin as a transport substrate and supportsthe results shown in Table 1. Therefore, MATE1 is considered to be amelatonin transporter in the pineal body cells. Furthermore, since humanMATE1 and mouse MATE1 have a very high homology, it is inferred thatMATE1 plays similar roles in humans.

Furthermore, mouse MATE2 was found to be expressed specifically in thetesticle Leydig cells, which secrete steroid hormones such astestosterone in the testicle (FIG. 19). This indirectly suggests thatMATE2 transports steroid hormones and supports the results shown inTable 1. Therefore, MATE2 is considered to be a steroid hormonetransporter. Since human MATE3 and mouse MATE2 have a very highhomology, and the expression sites are similar (FIG. 20), MATE2 isconsidered to play similar roles in humans.

Furthermore, quercetin, a plant flavonoid, is known to be accumulated invacuoles of plants, but the function thereof is unknown. According tothe present invention, it is suggested that MATE1-like transporterfunctions as a transporter of plant flavonoids in a plant.

Since MATE1 and MATE2 are expressed in organs other than the kidneys andthe liver, it is suggested that MATE-type transporters have functionsother than that of the OC transporter. That is, it appears thatMATE-type transporters functionally control transport of physiologicalmetabolites having various sizes, structures, and hydrophobicity and areresponsible for the molecular mechanism for maintaining electrolytehomeostasis in an organism.

It is known that the MATE gene is included in about 80 deficient genesin patients with Smith-Magenis syndrome, which is caused by abnormal17q11.2 chromosome and presents diverse congenital deformities and mildmental growth retardation (for example, refer to Non-patent Documents 16and 17). It is considered that patients with Smith-Magenis syndrome lackthe H⁺/OC transporter, and further studies based on the presentinvention can clarify the relationship between symptoms of this syndromeand the MATE family. Furthermore, the mammal MATE molecule of thepresent invention can bring about a breakthrough in studies ofinteractions of toxins, chemicals, and metabolites in an organism, genepolymorphism, and gene mutation. Furthermore, it is considered that, inplants, MATE of the plant is involved in resistance to chemicals orresistance to endogenous toxic metabolites. Thus, the MATE family isfundamental OC transporters in nature and plays a wide variety of rolesin excretion of OCs and related compounds thereof.

It is noted that specific embodiments or examples explained in the BestMode for Carrying Out the Invention are intended to clarify thetechnical content of the present invention, and the present inventionshould not be construed in any limitative way to such specific examplesand can be implemented with various changes unless they depart from thespirit of the present invention and the following appended claims.

INDUSTRIAL APPLICABILITY

A chemical that regulates excretion of a chemical and/or a waste (forexample, drugs, agricultural chemicals, and the like) can be screenedfor by using the present invention. Furthermore, nephrotoxicity and/orhepatotoxicity of a chemical can be tested by using the presentinvention. Furthermore, the present invention can be utilized as anexperimental system for measuring transport, secretion, accumulation, orexcretion of many biological components (in particular, highlyhydrophobic biological components) such as absorption or excretion ofmonoamines, volatile organic cations, and nicotine, secretion,absorption, or excretion of melatonin, steroid hormones, sex hormones,and related formulations thereof, and concentration of plant alkanoids(alkaloids) or phenols in the plant body, and so forth.

Since a chemical that regulates excretion of a chemical and/or a waste(for example, drugs, agricultural chemicals, and the like), which hasnot been found so far, can be screened for by using the presentinvention, and the present invention can contribute to development ofnew medical and pharmaceutical fields. Furthermore, since nephrotoxicityand/or hepatotoxicity of an arbitrary chemical can be tested by usingthe present invention, the present invention can promote researches inmedicine/pharmacy and contribute to development of research tools.

1-36. (canceled)
 37. A method for screening a substance which istransported through a membrane via a protein responsible for the finalstage of excretion of organic cation in a kidney or liver of a mammal,comprising the step of incubating a lipid membrane comprising one of thefollowing polypeptides together with a candidate factor: a polypeptideconsisting of the amino acid sequence of SEQ ID NO: 2 or 6; or apolypeptide which consists of an amino acid sequence wherein one or moreamino acids are deleted, substituted, or added in the amino acidsequence of SEQ ID NO: 2 or 6 and has a transporter activity in a cellmembrane.
 38. The method according to claim 37, further comprising astep of providing a pH gradient wherein pH decreases towards thedirection to which the candidate factor is transported, between the twodomains subdivided by the lipid membrane.
 39. The method according toclaim 38, wherein the lipid membrane forms a vesicle in which the innerpH is lower than the outer pH.
 40. The method according to claim 39,wherein the pH inside the vesicle is 6.5-7.5, and the pH outside thevesicle is 8.0-8.5.
 41. The method according to any one of claims 37 to40, wherein the lipid membrane further comprises H⁺-ATPase protein. 42.A kit for screening for a substance which is transported through amembrane via a protein responsible for the final stage of excretion oforganic cation in a kidney or liver of a mammal, comprising a lipidmembrane containing one of the following polypeptides: a polypeptideconsisting of the amino acid sequence of SEQ ID NO: 2 or 6; or apolypeptide which consists of an amino acid sequence wherein one or moreamino acids are deleted, substituted, or added in the amino acidsequence of SEQ ID NO: 2 or 6 and has a transporter activity in a cellmembrane.
 43. The kit according to claim 42, wherein the lipid membranefurther comprises H⁺-ATPase protein.
 44. A method for screening for achemical which regulates substance transport across a cell membrane viaa protein responsible for the final stage of excretion of organic cationin a kidney or liver of a mammal, comprising the step of incubating alipid membrane containing one of the following polypeptides togetherwith the substance and the candidate factor: a polypeptide consisting ofthe amino acid sequence of SEQ ID NO: 2 or 6; or a polypeptide whichconsists of an amino acid sequence wherein one or more amino acids aredeleted, substituted, or added in the amino acid sequence of SEQ ID NO:2 or 6 and has a transporter activity in a cell membrane.
 45. The methodaccording to claim 44, wherein the substance is tetraethylammonium(TEA), 1-methyl-4-phenylpyridinium (MPP), nicotine, cimetidine,quinidine, verapamil or quinine.
 46. The method according to claim 44 or45, further comprising a step of providing a pH gradient wherein pHdecreases towards the direction to which the candidate factor istransported, between the two domains subdivided by the lipid membrane.47. The method according to claim 46, wherein the lipid membrane forms avesicle in which the inner pH is lower than the outer pH.
 48. The methodaccording to claim 47, wherein the pH inside the vesicle is 6.5-7.5, andthe pH outside the vesicle is 8.0-8.5.
 49. The method according to anyone of claims 44 to 48, wherein the lipid membrane further comprisesH⁺-ATPase protein.
 50. A kit for screening for a chemical whichregulates substance transport across a cell membrane via a proteinresponsible for the final stage of excretion of organic cation in akidney or liver of a mammal, comprising a lipid membrane containing oneof the following polypeptides, and the substance: a polypeptideconsisting of the amino acid sequence of SEQ ID NO: 2 or 6; or apolypeptide which consists of an amino acid sequence wherein one or moreamino acids are deleted, substituted, or added in the amino acidsequence of SEQ ID NO: 2 or 6 and has a transporter activity in a cellmembrane.
 51. The kit according to claim 50, wherein the lipid membraneis tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP),nicotine, cimetidine, quinidine, verapamil or quinine.
 52. The kitaccording to claim 50 or 51, wherein the substance further comprisesH⁺-ATPase protein.
 53. A lipid membrane comprising one of the followingpolypeptides: a polypeptide consisting of the amino acid sequence of SEQID NO: 6; or a polypeptide which consists of an amino acid sequencewherein one or more amino acids are deleted, substituted, or added inthe amino acid sequence of SEQ ID NO: 6 and that is responsible for thefinal stage of excretion of organic cation in a kidney or liver of amammal.
 54. The lipid membrane according to claim 53, which is anaturally occurring lipid membrane.
 55. The lipid membrane according toclaim 54, wherein the lipid membrane is a cell membrane or a membranevesicle.
 56. The lipid membrane according to claim 53, wherein the lipidmembrane is an artificial lipid membrane.
 57. The lipid membraneaccording to claim 56, wherein the lipid membrane is a planar lipidmembrane or a liposome.
 58. The lipid membrane according to claim anyone of claims 53 to 57, wherein the lipid membrane further comprisesH⁺-ATPase protein.
 59. A method for preparing the lipid membraneaccording to claim 53, comprising the step of using a vector containinga polynucleotide encoding one of the following polypeptides: apolypeptide consisting of the amino acid sequence of SEQ ID NO: 6; or apolypeptide which consists of an amino acid sequence wherein one or moreamino acids are deleted, substituted, or added in the amino acidsequence of SEQ ID NO: 6 and that is responsible for the final stage ofexcretion of organic cation in a kidney or liver of a mammal.
 60. A kitfor preparing the lipid membrane according to claim 53, comprising avector containing a polynucleotide encoding one of the followingpolypeptides: a polypeptide consisting of the amino acid sequence of SEQID NO: 6; or a polypeptide which consists of an amino acid sequencewherein one or more amino acids are deleted, substituted, or added inthe amino acid sequence of SEQ ID NO: 6 and that is responsible for thefinal stage of excretion of organic cation in a kidney or liver of amammal.
 61. A lipid membrane containing one of the followingpolypeptides: a polypeptide consisting of the amino acid sequence of SEQID NO: 4 or 8; or a polypeptide which consists of an amino acid sequencewherein one or more amino acids are deleted, substituted, or added inthe amino acid sequence of SEQ ID NO: 4 or 8 and that is responsible forthe final stage of excretion of organic cation in a kidney or liver of amammal.
 62. The lipid membrane according to claim 61, wherein the lipidmembrane is a naturally occurring lipid membrane.
 63. The lipid membraneaccording to claim 62, wherein the lipid membrane is a cell membrane ora membrane vesicle.
 64. The lipid membrane according to claim 61,wherein the lipid membrane is an artificial lipid membrane.
 65. Thelipid membrane according to claim 61, wherein the lipid membrane is aplanar lipid membrane or a liposome.
 66. The lipid membrane according toany one of claims 61 to 65, wherein the lipid membrane further comprisesH⁺-ATPase protein.
 67. A method for preparing the lipid membraneaccording to claim 61, comprising the step of using a vector containinga polynucleotide encoding one of the following polypeptides: apolypeptide consisting of the amino acid sequence of SEQ ID NO:4 or 8;or a polypeptide which consists of an amino acid sequence wherein one ormore amino acids are deleted, substituted, or added in the amino acidsequence of SEQ ID NO: 4 or 8 and that is responsible for the finalstage of excretion of organic cation in a kidney or liver of a mammal.68. A kit for preparing the lipid membrane according to claim 61,comprising a vector containing a polynucleotide encoding one of thefollowing polypeptides: a polypeptide consisting of the amino acidsequence of SEQ ID NO: 4 or 8; or a polypeptide which consists of anamino acid sequence wherein one or more amino acids are deleted,substituted, or added in the amino acid sequence of SEQ ID NO: 4 or 8and that is responsible for the final stage of excretion of organiccation in a kidney or liver of a mammal.
 69. A method for screening asubstance which is transported through a membrane via a proteinresponsible for the final stage of excretion of organic cation in akidney or liver of a mammal, comprising the step of incubating a lipidmembrane containing one of the following polypeptides together with acandidate factor: a polypeptide consisting of the amino acid sequence ofSEQ ID NO: 4 or 8; or a polypeptide which consists of an amino acidsequence wherein one or more amino acids are deleted, substituted, oradded in the amino acid sequence of SEQ ID NO: 4 or 8 and has atransporter activity in a cell membrane.
 70. The method according toclaim 69, further comprising a step of providing a pH gradient whereinpH decreases towards the direction to which the candidate factor istransported, between the two domains subdivided by the lipid membrane.71. The method according to claim 70, wherein the lipid membrane forms avesicle in which the inner pH is lower than the outer pH.
 72. The methodaccording to claim 70, wherein the pH inside the vesicle is 6.5-7.5, andthe pH outside the vesicle is 8.0-8.5.
 73. The method according to anyone of claims 69 to 72, wherein the lipid membrane further comprisesH⁺-ATPase protein.
 74. A kit for screening for a substance which istransported through a membrane via a protein responsible for the finalstage of excretion of organic cation in a kidney or liver of a mammal,comprising a lipid membrane containing one of the followingpolypeptides. a polypeptide consisting of the amino acid sequence of SEQID NO: 4 or 8; or a polypeptide which consists of an amino acid sequencewherein one or more amino acids are deleted, substituted, or added inthe amino acid sequence of SEQ ID NO: 4 or 8 and has a transporteractivity in a cell membrane.
 75. The kit according to claim 74, whereinthe lipid membrane further comprises H⁺-ATPase protein.
 76. A method forscreening for a chemical which regulates substance transport across acell membrane via a protein responsible for the final stage of excretionof organic cation in a kidney or liver of a mammal, comprising the stepof incubating a lipid membrane containing one of the followingpolypeptides together with the substance and the candidate factor: apolypeptide consisting of the amino acid sequence of SEQ ID NO: 4 or 8;or a polypeptide which consists of an amino acid sequence wherein one ormore amino acids are deleted, substituted, or added in the amino acidsequence of SEQ ID NO: 4 or 8 and has a transporter activity in a cellmembrane.
 77. The method according to claim 76, wherein the substance istetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), nicotine,cimetidine, quinidine, verapamil or quinine.
 78. The method according toclaim 76 or 77, further comprising a step of providing a pH gradientwherein pH decreases towards the direction to which the candidate factoris transported, between the two domains subdivided by the lipidmembrane.
 79. The method according to claim 78, wherein the lipidmembrane forms a vesicle in which the inner pH is lower than the outerpH.
 80. The method according to claim 79, wherein the pH inside thevesicle is 6.5-7.5, and the pH outside the vesicle is 8.0-8.5.
 81. Themethod according to any one of claims 76 to 80, wherein the lipidmembrane further comprises H⁺-ATPase protein.
 82. A kit for screeningfor a chemical which regulates substance transport across a cellmembrane via a protein responsible for the final stage of excretion oforganic cation in a kidney or liver of a mammal, comprising a lipidmembrane containing one of the following polypeptides, and thesubstance: a polypeptide consisting of the amino acid sequence of SEQ IDNO: 4 or 8; or a polypeptide which consists of an amino acid sequencewherein one or more amino acids are deleted, substituted, or added inthe amino acid sequence of SEQ ID NO: 4 or 8 and has a transporteractivity in a cell membrane.
 83. The kit according to claim 82, whereinthe lipid membrane is tetraethylammonium (TEA),1-methyl-4-phenylpyridinium (MPP), nicotine, cimetidine, quinidine,verapamil or quinine.
 84. The kit according to claim 82 or 83, whereinthe lipid membrane further comprises H⁺-ATPase protein.